SRXH 10-Q
SRX Global Inc. (SRXH)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
Or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) (Zip Code) | (Registrant’s Telephone Number, Including Area Code) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files.)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | ☒ | Smaller reporting company | Emerging growth company |
If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate
by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date was: shares of $ par value common stock outstanding as of August 13, 2026.
SRX Global Inc. (formerly SRx Health Solutions, Inc.)
TABLE OF CONTENTS
| 2 |
FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “should,” “will,” “would,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. They appear in a number of places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including, but not limited to, those summarized below:
| ● | the impact of damage to or interruption of our information technology systems due to cyber-attacks or other circumstances beyond our control; |
| ● | business interruptions resulting from geopolitical actions, including war and terrorism; |
| ● | our ability to successfully implement our growth strategy; |
| ● | failure to achieve growth or manage anticipated growth; |
| ● | our ability to achieve or maintain profitability; |
| ● | the loss of key members of our senior management team; |
| ● | our ability to generate sufficient cash flow or raise capital on acceptable terms to run our operations, service our debt and make necessary capital expenditures; |
| ● | our dependence on our subsidiaries for payments, advances and transfers of funds due to our holding company status; |
| ● | our ability to successfully develop additional products and services or successfully market and commercialize such products and services; |
| ● | competition in our market; |
| ● | our ability to attract new and retain existing customers, suppliers, distributors or retail partners; |
| ● | allegations that our products cause injury or illness or fail to comply with government regulations; |
| ● | our ability to manage our supply chain effectively; |
| ● | our or our co-manufacturers’ and suppliers’ ability to comply with legal and regulatory requirements; |
| ● | the effect of potential price increases and shortages on the inputs, commodities and ingredients that we require, whether as a result of the continued actual or perceived effects of broader geopolitical and macroeconomic conditions, including the military conflict between Russia and Ukraine; |
| 3 |
| ● | our ability to develop and maintain our brand and brand reputation; |
| ● | compliance with data privacy rules; |
| ● | our compliance with applicable regulations issued by the U.S. Food and Drug Administration (“FDA”), the U.S. Federal Trade Commission (“FTC”), the U.S. Department of Agriculture (“USDA”), and other federal, state and local regulatory authorities, including those regarding marketing pet food, products and supplements; |
| ● | risk of our products being recalled for a variety of reasons, including product defects, packaging safety and inadequate or inaccurate labeling disclosure; |
| ● | risk of shifting customer demand in relation to raw pet foods, premium kibble and canned pet food products, and failure to respond to such changes in customer taste quickly and effectively; and |
| ● | the other risks identified in this Quarterly Report including, without limitation, Part I, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Part II, Item 1A “Risk Factors” as such factors may updated from time to time in our other public filings. |
While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.
NOTE REGARDING TRADEMARKS
We own or have rights to use the trademarks and trade names that we use in conjunction with the operation of our business. Each trademark or trade name of any other company appearing in this Quarterly Report on Form 10-Q is, to our knowledge, owned by such other company. Solely for convenience, our trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the ® or ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and trade names.
| 4 |
PART I
| ITEM 1. | FINANCIAL STATEMENTS |
SRX Global Inc. (formerly SRx Health Solutions, Inc.)
Unaudited Condensed Consolidated Statements of Operations
(Dollars in thousands, except share and per share amounts)
| Three
Months Ended June 30, | Nine
Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | $ | $ | $ | ||||||||||||
| Cost of goods sold | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Loss from continuing operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expense (income): | ||||||||||||||||
| Interest expense, net | ( | ) | ( | ) | ||||||||||||
| Loss/(Gain) on extinguishment of debt | ( | ) | ||||||||||||||
| Change in fair value of digital assets | ||||||||||||||||
| Change in fair value of equity securities | ( | ) | ||||||||||||||
| Change in fair value of derivative liabilities | ( | ) | ( | ) | ||||||||||||
| Bargain purchase gain | ( | ) | ( | ) | ||||||||||||
| Other income, net | ( | ) | ( | ) | ||||||||||||
| Total other expense, net | ( | ) | ( | ) | ||||||||||||
| Net loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | ||||||||||||||||
| Net loss from continuing operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss from discontinued operations | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares outstanding, basic | ||||||||||||||||
| Weighted average number of shares outstanding, diluted | ||||||||||||||||
| Loss per share, basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Loss per share, diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 5 |
SRX Global Inc. (formerly SRx Health Solutions, Inc.)
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except share and per share amounts)
| June 30, 2026 | September 30, 2025 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash | ||||||||
| Short-term investments | ||||||||
| Accounts receivable, net | ||||||||
| Inventories, net | ||||||||
| Notes receivable | ||||||||
| Digital assets | ||||||||
| Investment in equity securities | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total Current Assets | ||||||||
| Fixed assets, net | ||||||||
| Intangible assets, net | ||||||||
| Right-of-use assets, operating leases | ||||||||
| Other assets | ||||||||
| Total Assets | $ | $ | ||||||
| Liabilities & Stockholders’ Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Operating lease liability, short-term | ||||||||
| Total Current Liabilities | ||||||||
| Convertible debt, long-term | ||||||||
| Total Liabilities | ||||||||
| Stockholders’ Equity | ||||||||
| Common Stock, $ par value, shares authorized, & shares issued and outstanding as of June 30, 2026, and September 30, 2025, respectively | ||||||||
| Preferred Stock, $ par value, shares authorized, & shares issued and outstanding as of June 30, 2026 and September 30, 2025, respectively | ||||||||
| Additional paid-in capital, common stock | ||||||||
| Additional paid-in capital, preferred stock | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Equity | ||||||||
| Total Liabilities and Stockholders’ Equity | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 6 |
SRX Global Inc. (formerly SRx Health Solutions, Inc.)
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
(Dollars in thousands, except shares)
| Common Stock | Accumulated Other Comprehensive | Additional Paid-In | Accumulated | Total Stockholders’ | ||||||||||||||||||||
| Shares | Amount | Income | Capital | Deficit | Equity | |||||||||||||||||||
| Balance as of September 30, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Share-based compensation | $ | |||||||||||||||||||||||
| Settlement of RSUs | ( | ) | $ | ( | ) | |||||||||||||||||||
| Conversion of convertible debt | ( | ) | $ | ( | ) | |||||||||||||||||||
| Share issuance | $ | |||||||||||||||||||||||
| Warrant exercises | $ | |||||||||||||||||||||||
| Share redemption | ( | ) | $ | |||||||||||||||||||||
| Equity issued in business combinations | $ | |||||||||||||||||||||||
| Net loss | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Balance as of December 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Share-based compensation | $ | |||||||||||||||||||||||
| Conversion of convertible debt | $ | |||||||||||||||||||||||
| Share issuance for professional services | $ | |||||||||||||||||||||||
| Shares issued for settle of accounts payable | $ | |||||||||||||||||||||||
| Shares issued for private placement | $ | |||||||||||||||||||||||
| Warrant exercises | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Net loss | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Balance as of March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Capital contributions for settlement of historical related party loans | — | |||||||||||||||||||||||
| Shares redeemed in connection with business combinations* | ( | ) | ( | ) | ( | ) | $ | ( | ) | |||||||||||||||
| Share-based compensation, post-merger | $ | |||||||||||||||||||||||
| Shares issued for private placement, post-merger | $ | |||||||||||||||||||||||
| Shares issued for acquisition costs | $ | |||||||||||||||||||||||
| Fair value of shares issued to acquire Better Choice | $ | |||||||||||||||||||||||
| Shares repurchased | ( | ) | ( | ) | $ | ( | ) | |||||||||||||||||
| Warrant exercises | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Exercise of pre-funded warrants | $ | |||||||||||||||||||||||
| Net loss | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Foreign currency translation adjustment | — | $ | ||||||||||||||||||||||
| Cumulative translation adjustment related to discontinued operations | — | ( | ) | $ | ( | ) | ||||||||||||||||||
| Balance as of June 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| * |
| 7 |
| Common Stock | Series A Preferred Stock | Series B Preferred Stock | Additional Paid-In Capital - | Additional Paid-In Capital - | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Common | Preferred | Deficit | Equity | |||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Share-based compensation | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Exercise of prefunded warrants | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Retraction of exchangeable shares and conversion to common stock | — | — | $ | |||||||||||||||||||||||||||||||||||||
| ELOC shares issued | — | — | $ | |||||||||||||||||||||||||||||||||||||
| ELOC Commitment Note | — | — | — | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||
| Issuance of Series A convertible preferred stock and warrants | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Debt extinguishment and Series A issuance | — | — | — | $ | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||
| Balance as of December 31, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Warrant exercises | — | — | ( | ) | $ | |||||||||||||||||||||||||||||||||||
| Retraction of exchangeable shares and conversion to common stock | — | — | $ | |||||||||||||||||||||||||||||||||||||
| ELOC shares issued | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Conversion of Series A convertible preferred stock | ( | ) | — | ( | ) | $ | ||||||||||||||||||||||||||||||||||
| Redemption and cancellation of Series A convertible preferred stock | — | ( | ) | — | ( | ) | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| Issuance of Series B convertible preferred stock and warrants | — | $ | ||||||||||||||||||||||||||||||||||||||
| Share repurchase | ( | ) | — | — | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||
| Balance as of March 31, 2026 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Conversion of ELOC Commitment Note | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Warrant exercises | — | — | $ | |||||||||||||||||||||||||||||||||||||
| EMJX consideration shares issued | — | — | $ | |||||||||||||||||||||||||||||||||||||
| ELOC shares issued | — | — | $ | |||||||||||||||||||||||||||||||||||||
| Proceeds from prior-period issuance of Series B Preferred Stock | — | — | — | $ | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||
| Balance as of June 30, 2026 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 8 |
SRX Global Inc. (formerly SRx Health Solutions, Inc.)
Unaudited Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
| Nine Months Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash Flow from Operating Activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ( | ) | ||||||
| Non-cash fixed assets adjustment | ||||||||
| Bargain purchase gain | ( | ) | ||||||
| Gain on disposal of assets, net | ( | ) | ||||||
| Share-based compensation | ||||||||
| Debt discount amortization | ||||||||
| Equity offering-related parties | ||||||||
| Bad debt expense | ( | ) | ||||||
| Income tax provision | ||||||||
| Change in fair value of digital assets | ||||||||
| Change in fair value of equity securities | ||||||||
| Change in fair value of derivative liabilities | ( | ) | ||||||
| Loss on settlement of debt | ||||||||
| Other | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | ||||||||
| Inventories, net | ( | ) | ||||||
| Prepaid expenses and other assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued liabilities | ||||||||
| Cash Used in Operating Activities | $ | ( | ) | $ | ( | ) | ||
| Cash Flow from Investing Activities: | ||||||||
| Acquisition of EMJX | ( | ) | ||||||
| Short-term investments, net | ( | ) | ||||||
| Purchase of digital assets | ( | ) | ||||||
| Proceeds from sale of digital assets | ||||||||
| Purchase of equity securities | ( | ) | ||||||
| Proceeds from sale of equities and option contracts (active trades) | ||||||||
| Purchases of equities and option contracts (active trades) | ( | ) | ||||||
| Purchase of convertible note receivable | ( | ) | ||||||
| Cash paid to SRx Canada | ( | ) | ||||||
| Proceeds from sale of convertible note receivable | ||||||||
| Cash Used in Investing Activities | $ | ( | ) | $ | ( | ) | ||
| Cash Flow from Financing Activities: | ||||||||
| Proceeds from issuance of common stock | ||||||||
| Proceeds from issuance of convertible preferred stock | ||||||||
| Redemption of Series A convertible preferred stock | ( | ) | ||||||
| Repayment of convertible debt | ( | ) | ||||||
| Cash paid for financing costs | ( | ) | ||||||
| Proceeds from warrant exercises | ||||||||
| Repurchase of common stock | ( | ) | ||||||
| Proceeds from short-term borrowings | ||||||||
| Proceeds from Wintrust facility | ||||||||
| Payments on Wintrust facility | ( | ) | ||||||
| Proceeds from PIPE | ||||||||
| PIPE out | ( | ) | ||||||
| Payments for share repurchase | ( | ) | ||||||
| Cash Provided by (Used in) Financing Activities | $ | $ | ( | ) | ||||
| Net cash provided by (used in) continuing operations | $ | $ | ( | ) | ||||
| Net cash provided by discontinued operations | ||||||||
| Net increase in cash and cash equivalents | ||||||||
| Effect of foreign currency translation adjustments | ||||||||
| Total cash and cash equivalents, beginning of period | ||||||||
| Total cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental schedule of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Disclosure of non-cash financing activities: | ||||||||
| Convertible note settled via reduction in equity consideration | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 9 |
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Note 1 – Nature of business and summary of significant accounting policies
Nature of the business
SRx Global Inc. (formerly SRx Health Solutions and prior to that Better Choice Company, Inc.) and its subsidiaries are together referred to in these consolidated financial statements as the “Company.”
On June 18, 2026, the Company changed its legal name from “SRx Health Solutions, Inc.” to “SRX Global Inc.” The Company’s stock will remain trading on the NYSE under the ticker symbol “SRXH.”
The Company legal name change coincided with the completion of the Company’s acquisition of EMJ Crypto Technologies Inc. (“EMJC”), CCC Crypto Corp., and related intellectual property assets, pursuant to which the Company acquired a proprietary artificial intelligence-driven digital-asset treasury management platform. In connection with the acquisition, the Company shifted its strategic focus from its historical pet health and wellness business, conducted under the Halo brand, to an AI-enabled investment platform focused on digital-asset treasury management and related high-conviction investment strategies, while continuing to operate its legacy Halo pet health and wellness business, as further described in Note 2 – Asset acquisition.
On April 24, 2025, SRx Health Solutions, Inc., a corporation incorporated under the laws of the Province of Ontario on April 26, 2022 (“SRx Canada” or the “Accounting Acquirer”), consummated a business combination (the “Merger”) with Better Choice Company, Inc., a Delaware corporation (“Better Choice” or the “Legal Acquirer”). In the Merger, 1000994476 Ontario Inc. (“AcquireCo”), an indirect wholly-owned subsidiary of Better Choice, amalgamated with and into SRx Canada, with SRx Canada surviving the amalgamation and continuing its operations under the new legal name SRx Health Solutions (Canada) Inc. (“SRx Canada”), an indirect wholly-owned subsidiary of Better Choice.
In connection with the Merger, Better Choice changed its corporate name to “SRx Health Solutions, Inc.,” and adopted the operations of the Accounting Acquirer as its primary business. As such, SRx Canada is the continuing reporting entity for accounting purposes. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes in the Company’s Annual Report for the year ended September 30, 2025, filed with the SEC on December 5, 2025.
SRx Canada’s registered head office was originally located at 65 Queen Street West, Suite 800, Toronto, Ontario, M5H 2M5. Post the Merger, the Company’s registered head office remained at 801 US Highway 1, North Palm Beach, Florida 33408.
Effective during the year ended September 30, 2025, the Company made the strategic decision to discontinue the operations of its Canadian pharmacy and healthcare services business conducted through SRx Canada. On August 12, 2025, SRx Canada initiated restructuring proceedings under the Companies’ Creditors Arrangement Act (“CCAA”) in Canada. As a result, the SRx healthcare business is classified and presented as a discontinued operation in these consolidated financial statements in accordance with ASC 205-20. The CCAA proceedings relate exclusively to the discontinued SRx Canada healthcare business and do not impact the Company’s continuing pet food and pet wellness operations. Following the discontinuation, the Company’s continuing operations consist solely of its premium pet health and nutrition products segment operated through Halo, Purely for Pets, Inc. Additional information regarding the discontinued operations, CCAA proceedings, and the associated financial reporting impacts is provided in Note 22 – Discontinued operations.
Halo Spin-Out Distribution
On
April 25, 2025, the Company distributed (the “Spin-Out Distribution”) to the Better Choice stockholders of record as of April
23, 2025 (the “Record Stockholders”) one share of Class A Common Stock, par value $, of Halo Spin-Out SPV Inc., a Delaware
corporation (“Halo SPV”), for every one share of Better Choice common stock held by the Record Stockholders. Halo SPV held
The ownership of Halo SPV following the Spin-Out Distribution mirrored the ownership of Better Choice immediately prior to the Merger and the Spin-Out Distribution. As such, the Record Stockholders, who received the Halo SPV shares, are the same ultimate owners who indirectly held Halo prior to the Spin-Out Distribution. Accordingly, the Spin-Out Distribution did not result in a substantive change in ownership of Halo from the perspective of the Company’s consolidated financial statements. In accordance with ASC 810, Consolidation, the Spin-Out Distribution represented a reorganization of ownership interests under common control and was therefore treated as a common control equity reorganization, with transfers of interests accounted for as equity transactions. Halo continues to be fully consolidated, with no change in the Company’s accounting treatment.
On
August 21, 2025, the Company entered into a Share Exchange Agreement (the “Exchange Agreement”) with Halo Spin-Out SPV, whereby
the Company acquired the
| 10 |
Statement of Compliance
The Company’s condensed consolidated financial statements are prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial reports and accounting principles generally accepted in the U.S.(“GAAP”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended June 30, 2026 are not necessarily indicative of the results that may be expected for any other reporting period.
These condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise stated in the significant accounting policies. These condensed consolidated financial statements are presented in U.S. dollars and all values are rounded to the nearest thousand ($000), except when otherwise indicated.
These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes in the Company’s Annual Report for the year ended September 30, 2025, filed with the SEC on December 5, 2025.
Consolidation
The condensed consolidated financial statements comprise the financial statements of the Company and its wholly owned subsidiaries. When the Company does not own all of the equity in a subsidiary, the non-controlling interest is disclosed as a separate line item in the condensed consolidated statements of financial position and the earnings accruing to non-controlling interest holders are disclosed as a separate line item in the condensed consolidated statements of operations. The financial results of subsidiaries are included in the condensed consolidated financial statements from the date on which control commences, until the date on which control ceases. Intercompany balances and transactions are eliminated upon consolidation. Control is achieved when the Company is exposed to, or has the right to, variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.
NYSE American Listing Compliance and Reverse Stock Split
On June 23, 2026, the Company was informed by the NYSE American LLC (the “NYSE American”) that it was not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide, which relates to low selling price per share for a substantial period of time. The Company’s common stock closed below $ on June 23, 2026, and NYSE American halted trading of the Company’s common stock, with the halt to continue until the Company effectuated a reverse stock split.
In
response, on June 24, 2026, the Company announced its plan to proceed with a
Going Concern
The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the ordinary course of business. The Company has historically incurred operating losses and experienced negative operating cash flows; however, management has implemented actions to improve liquidity and operating performance, including cost-reduction initiatives, margin improvement measures, and securing additional financing, as further described in Note 10 – Debt.
After considering these actions and the Company’s cash flow forecasts for the twelve months following the issuance of these consolidated financial statements, management believes the Company will have sufficient liquidity to meet its obligations as they become due. Accordingly, management has determined that there are no material uncertainties that cast doubt on the Company’s going concern status, and management has a reasonable expectation that the Company has adequate resources to continue in operational existence beyond June 30, 2026, and the condensed consolidated financial statements continue to be prepared using the going concern assumption.
Fiscal, Regulation and Other Federal Policies
Significant changes in, and uncertainty with respect to, legislation, regulation, government policy and economic conditions could adversely affect the Company’s business. Specific legislative and regulatory proposals that could have a material impact on the Company include, but are not limited to, modifications to international trade policy (such as tariffs); public company reporting requirements; and environmental regulation.
| 11 |
The Company cannot predict what actions may ultimately be taken with respect to tariffs or trade relations between the U.S. and other countries, what products may be subject to such actions, or what actions may be taken by the other countries in retaliation. Accordingly, it is difficult to predict how such actions may impact the Company’s business, or the business or habits of its customers. The Company’s business operations, as well as the businesses of its customers on which it is substantially dependent, are located in countries at risk for escalating trade disputes, including the U.S. Any resulting trade wars could have a significant adverse effect on world trade and could adversely impact the Company’s condensed consolidated financial condition, results of operations and cash flows.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. On an ongoing basis, the Company evaluates these assumptions, judgments and estimates. Actual results may differ from these estimates.
In the opinion of management, the condensed consolidated financial statements contain all adjustments necessary for a fair statement of the results of operations for the three and nine months ended June 30, 2026 and 2025, the financial position as of June 30, 2026 and September 30, 2025 and the cash flows for the nine months ended June 30, 2026 and 2025.
Summary of significant accounting policies
For additional information, please refer to the most recently filed Annual Report regarding the Company’s summary of significant accounting policies.
Asset acquisition
The Company evaluates each acquisition to determine whether the acquired set of assets and activities meets the definition of a business under ASC 805. When substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, or when the acquired set does not otherwise meet the definition of a business, the transaction is accounted for as an asset acquisition under ASC 805-50, Business Combinations — Related Issues.
The cost of an asset acquisition is measured as the total consideration transferred, including the fair value of any equity securities issued, plus direct transaction costs incurred to effect the acquisition. Direct transaction costs are capitalized as part of the cost of the assets acquired, rather than expensed as incurred.
The total cost of the acquisition is allocated to the identifiable assets acquired and liabilities assumed on a relative fair value basis. If the fair value of the identifiable net assets acquired cannot be individually and reliably measured for each asset, any excess of the total consideration over the fair value of the other identifiable net assets acquired is allocated to the remaining identifiable assets, typically the asset representing the primary economic substance of the transaction, on a relative fair value basis.
No goodwill is recognized in an asset acquisition, and any excess or shortfall between consideration transferred and the fair value of identifiable net assets is captured entirely within the allocation to the identifiable assets acquired.
At the acquisition date, the Company assesses the classification and designation of the financial assets and liabilities assumed based on the contractual terms, economic conditions, and other relevant factors, including embedded derivatives in host contracts.
Following initial recognition, the assets acquired are subsequently accounted for in accordance with the accounting policies applicable to that asset class. In connection with the Transaction between the Company and EMJC described in Note 2 – Asset acquisition, substantially all consideration was preliminarily allocated to identifiable intangible assets, as the fair value of the other assets acquired and liabilities assumed did not approximate the total consideration transferred.
Cash and cash equivalents
Cash and cash equivalents include demand deposits held with banks and highly liquid investments with original maturities of ninety days or less at acquisition date. Cash and cash equivalents are stated at cost, which approximates fair value because of the short-term nature of these instruments.
Short-term investments
Short-term
investments consist primarily of investments in highly liquid U.S. Treasury securities with original maturities generally ranging up
to approximately six months at acquisition date. The Company’s short-term investment portfolio is managed on a rolling maturity
basis, with substantially all holdings expected to mature within six months of the balance sheet date. As of June 30, 2026, the Company
held approximately $
| 12 |
Interest
income earned on short-term investments is recognized within interest income on the condensed consolidated statements of operations.
Realized and unrealized gains and losses associated with short-term investments are recognized within other income, net on the condensed
consolidated statements of operations. During the three and nine months ended June 30, 2026, the Company recognized less than $
The Company determines the fair value of U.S. Treasury securities using quoted prices in active markets for identical assets and classifies such investments within Level 1 of the fair value hierarchy under ASC 820.
Accounts and notes receivable and allowance for credit losses
Accounts receivable consist of unpaid buyer invoices from the Company’s customers, credit card payments receivable from third-party credit card processing companies, and, from time to time, notes receivable arising from investment or financing transactions. Accounts receivable is stated at the amount billed to customers, net of point of sale and cash discounts. Notes receivable are recorded at amortized cost, net of any origination fees, discounts, or premiums, which are recognized as an adjustment to interest income using the effective interest method over the expected term of the instrument.
The Company assesses the collectability of all receivables on an ongoing basis by considering its historical credit loss experience, current economic conditions, and other relevant factors. Based on this analysis, an allowance for credit losses is recorded, and the provision is included within SG&A expense.
The
Company recorded approximately
Inventories
Inventories, consisting of finished goods available for sale as well as packaging materials, are valued using the first-in first-out (“FIFO”) method and are recorded at the lower of cost or net realizable value. Cost is determined on a standard cost basis and includes the purchase price, as well as inbound freight costs and packaging costs. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated selling expenses. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, shrinkage, or declining selling prices. Write-downs to inventory are non-reversible even when circumstances that previously caused inventories to be written down below cost no longer exist. The Company records consideration received from suppliers as a reduction to the cost of inventory. These amounts are recognized in cost of sales when the associated inventory is sold.
This policy applies to inventories held in continuing operations. Inventories related to the discontinued Health Solutions segment, previously consisting of SRx Canada pharmacy operations, are classified as assets of discontinued operations and are disclosed separately in Note 22 – Discontinued operations.
Digital assets
Pursuant to ASU 2023-08, Intangibles — Goodwill and Other — Crypto Assets: Accounting for and Disclosure of Crypto Assets, codified into ASC subtopic 350-60, in-scope crypto assets are required to be measured at fair value in the statement of financial position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period. ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard.
Based on the above, the Company has adopted ASU 2023-08 as of Q1 2026. Crypto assets holdings are classified as digital assets under ASC 350-60 and measured at fair value, with changes in fair value of digital assets recognized in net income. No adjustments or reclassifications are required for the quarter. Under ASU 2023-08, impairment analysis is no longer required. Change in fair value of digital assets are instead recorded in net income each period.
The Company determines the fair value of its digital assets in accordance with ASC 820, using quoted (unadjusted) prices in active markets on the Coinbase exchange, which the Company has identified as its principal market. Because valuation is based on observable quoted prices, digital assets are classified within Level 1 of the fair value hierarchy.
Fixed assets
Fixed assets are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, and depreciation expense is included within SG&A expense. Expenditures for normal repairs and maintenance are charged to operations as incurred. The cost of fixed assets that are retired or otherwise disposed of and the related accumulated depreciation are removed from the fixed asset accounts in the year of disposal, and the resulting gain or loss is included in SG&A expense.
| 13 |
The Company assesses potential impairments of its fixed assets whenever events or changes in circumstances indicate that the asset’s carrying value may not be recoverable. An impairment charge would be recognized when the carrying amount of the identified asset grouping exceeds its fair value and is not recoverable, which would occur if the carrying amount exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the identified asset grouping.
Intangible assets
The Company’s intangible assets consist of acquired intellectual property that has been determined to have an indefinite useful life. The Company evaluates whether an intangible asset has an indefinite useful life based on the absence of legal, regulatory, contractual, competitive, or other economic factors that limit the period over which the asset is expected to contribute to cash flows, as well as the Company’s ability to renew or maintain the associated rights indefinitely.
Intangible assets are initially measured at fair value on the acquisition date. For assets acquired through an asset acquisition, cost is based on the fair value assigned at the acquisition date, as described in Note 2 – Asset acquisition.
After initial measurement, indefinite-lived intangible assets are carried at cost less accumulated impairment losses and are not amortized. Rather, the Company tests such assets for impairment at least annually, and more frequently if events or circumstances indicate that the carrying value may be impaired. The Company assesses indefinite-lived intangible assets for impairment by comparing the asset’s carrying value to its estimated fair value. If the carrying value exceeds its fair value, an impairment loss is recognized in the statement of operations for the excess of carrying value over fair value, generally determined using a discounted cash flow or market approach with Level 3 inputs. Previously recognized impairment losses are not reversed in subsequent periods.
The Company reassesses the indefinite useful life determination each reporting period. If events or circumstances indicate that the asset no longer has an indefinite useful life, the Company will estimate a finite useful life and begin amortizing the asset prospectively over its remaining estimated useful life, with any resulting impairment recognized at the date of the change in determination.
Investments in equity securities
The Company’s investments in equity securities represent minority interests in other entities over which the Company does not have a controlling financial interest or significant influence. Equity securities are accounted for in accordance with ASC 321, Investments - Equity Securities.
The Company holds investments in marketable equity securities that are publicly traded, such as common stock. Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income each period. These marketable equity securities are classified within investment in equity securities on the condensed consolidated balance sheet with gains and losses recognized in change in fair value of equity securities on the condensed consolidated statements of operations.
The Company also holds non-marketable equity investments and are accounted for using the measurement alternative. Equity investments without readily determinable fair values, such as preferred stocks and warrants, are measured at cost, less impairment, and are adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer as of the respective transaction date.
The Company evaluates equity securities for impairment periodically or when events or changes in circumstances indicate the carrying amount may not be recoverable. When indicators of impairment exist and the estimated fair value of an investment is below its carrying amount, the Company writes down the investment to its fair value in interest and other income, net on the condensed consolidated statements of operations.
| 14 |
Derivatives and hedging activities
FASB ASC 815, Derivatives and Hedging (“ASC 815”), provides the disclosure requirements for derivatives and hedging activities with the intent to provide users of financial statements with an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how the entity accounts for derivative instruments and related hedged items, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. Further, qualitative disclosures are required that explain the Company’s objectives and strategies for using derivatives, as well as quantitative disclosures about the fair value of and gains and losses on derivative instruments.
As required by ASC 815, the Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting does not apply to the Company’s derivatives. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly in earnings as a component of other income.
Derivative instruments are measured using quoted market prices obtained from active markets and are classified as Level 1 fair value measurements under ASC 820, Fair Value Measurement. Gains and losses from derivative instruments are reported in the same income statement line item as gains and losses from other investment activities measured at fair value.
Convertible debt
The Company accounts for convertible debt instruments in accordance with ASC 470, Debt, and ASU 2020-06, which eliminated the requirement to separately account for embedded conversion features as equity when certain criteria are met. As such, convertible debt instruments that do not require separate derivative accounting under ASC 815 are accounted for entirely as liabilities and recorded at amortized cost. Debt issuance costs are capitalized and amortized to interest expense over the term of the instrument using the effective interest method. Upon conversion, the carrying amount of the debt is reclassified to equity with no gain or loss recognized. If a convertible instrument contains an embedded feature that does not qualify for the equity scope exception, it is accounted for separately as a derivative liability at fair value with changes recognized in earnings.
Preferred stock
The Company classifies its Series A and Series B convertible preferred stock as temporary or permanent equity based on the specific terms and conditions of the instrument and the guidance in ASC 480 and ASC 815. The Company evaluates embedded features, including conversion and redemption provisions, to determine whether such features require bifurcation as derivative liabilities or affect equity classification. Issuance proceeds are allocated to the preferred stock and any freestanding equity-classified instruments based on their relative fair values.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statement of operations. The Pre-Funded and Representative Warrants (as defined in Note 13 – Preferred stock, warrants and other equity) are equity classified.
Income taxes
Income taxes are recorded in accordance with ASC 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the condensed consolidated financial statements and tax bases of assets and liabilities and for loss and credit carryforwards using enacted tax rates anticipated to be in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized.
| 15 |
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that some or all the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. As of June 30, 2026 and September 30, 2025, the Company does not have any significant uncertain income tax positions. If incurred, the Company would classify interest and penalties on uncertain tax positions as income tax expense.
The Company was incorporated on May 6, 2019. Prior to this date, the Company operated as a flow through entity for state and U.S. federal tax purposes. The Company files a U.S. federal and state income tax return, including for its wholly owned subsidiaries.
Revenue
The Company generates revenue primarily from the sale of consumer products, including dry food, wet food, treats, and other premium pet products. Revenue is recognized in accordance with ASC 606, Revenue from Contracts with Customers, when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
The Company has concluded that it acts as the principal in its revenue arrangements, as it controls the goods before they are transferred to the customer. The Company does not have material financing components or significant variable consideration in its customer contracts.
Revenue from product sales is recognized when the products are shipped to the customer, which is the point at which control has transferred. Amounts billed and due from customers are recorded as accounts receivable. The Company provides for estimated sales returns and allowances, which are not material. Trade incentives, including customer pricing allowances, merchandising funds, and point-of-sale discounts, are recognized as reductions to revenue based on historical experience, estimated redemption rates, and management’s judgment.
Revenues from services formerly provided by the Health Solutions segment, including specialty healthcare services from SRx Canada, are presented as discontinued operations and are excluded from continuing operations.
The accounting policies for revenue recognition in the Consumer Products segment are consistent with those described above and in the accompanying condensed consolidated financial statements.
Cost of goods sold
Cost of goods sold consists primarily of the cost of product obtained from co-manufacturers, packaging materials, freight costs for shipping inventory to the warehouse, as well as third-party warehouse and order fulfillment costs.
Advertising
The
Company charges advertising costs to expense as incurred and such charges are included in selling, general and administrative
(“SG&A”) expense. The Company’s advertising expenses consist primarily of online advertising, search costs,
email advertising and radio advertising. In addition, the Company reimburses its customers and third parties for in-store activities
and records these costs as advertising expenses. Advertising costs were $
Share-based compensation awards are measured at their estimated fair value on each respective grant date. The Company recognizes share-based payment expenses over the requisite service period. The Company’s share-based compensation awards are subject only to service-based vesting conditions. Pursuant to ASC 718-10-35-8, the Company recognizes compensation cost for stock awards with only service conditions that have a graded vesting schedule on a straight-line basis over the service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards. Forfeitures are recognized as they occur.
In
April 2024, the Company’s board of directors authorized and approved a stock repurchase plan (the “Repurchase Plan”)
for up to $
| 16 |
Operating leases
The Company determines if a contract or arrangement meets the definition of a lease at inception. The Company has elected to make the accounting policy election for short-term leases. For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of lease payments over the term. Lease renewal options are only included in the measurement if the Company is reasonably certain to exercise the optional renewals. Any variable lease costs, other than those dependent upon an index or rate, are expensed as incurred. If a lease does not provide a readily available implicit rate, the Company estimates the incremental borrowing discount rate based on information available at lease commencement.
The Company has no operating leases as of June 30, 2026.
Fair value of financial instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy uses a framework which requires categorizing assets and liabilities into one of three levels based on the inputs used in valuing the asset or liability.
Level 1 inputs are unadjusted, quoted market prices in active markets for identical assets or liabilities.
Level 2 inputs are observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
Level 3 inputs include unobservable inputs that are supported by little, infrequent or no market activity and reflect management’s own assumptions about inputs used in pricing the asset or liability.
Level 1 provides the most reliable measure of fair value, while Level 3 generally requires significant management judgment. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s financial instruments recognized on the condensed consolidated balance sheets consist of cash and cash equivalents, restricted cash, short-term investments, trade accounts receivable, notes receivable, digital assets, investment in equity securities (marketable and non-marketable), derivative assets and liabilities, accounts payable, convertible debt, accrued liabilities and other liabilities.
Fair value measurements of non-financial assets and non-financial liabilities reflect Level 3 inputs and are primarily used to measure the estimated fair values of other intangible assets and long-lived assets impairment analyses.
Basic and diluted loss per share has been determined by dividing the net loss available to common stockholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. Common stock equivalents are excluded from the computation of diluted weighted average shares outstanding when their effect is anti-dilutive.
Segment information
Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and assess performance. The Company has determined that its Board of Directors functions as the CODM.
As of September 30, 2025, the Company reported a single reportable segment, Consumer Products, which includes the legacy Halo pet food business. As of June 30, 2026, following the acquisition of EMJX, the Company reports two reportable segments, Consumer Products and EMJX. The Consumer Products segment operates primarily in the United States and includes dry food, wet food, treats, and other premium pet products. The EMJX segment consists of the Company’s digital-asset treasury management platform and related investment strategy, including the use of artificial intelligence-driven technology to support capital allocation, hedging, and investment decision-making. The Health Solutions operations, previously reported as a separate segment, have been classified as discontinued operations as further described in Note 22 – Discontinued operations.
The Consumer Products and EMJX segments reflect the Company’s internal management structure and are evaluated by the CODM based on their operational models, economic characteristics, and financial performance. The accounting policies of the segments are consistent with those described in the accompanying condensed consolidated financial statements. See Note 19 – Segment information.
| 17 |
Discontinued operations
The Company classifies a component of its business as a discontinued operation when the operations and cash flows of the component can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the Company, and the component represents a strategic shift that will have a major effect on the Company’s operations and financial results.
Upon classification as a discontinued operation, the results of operations, cash flows, and related assets and liabilities of the component are presented separately in the condensed consolidated financial statements for all periods presented in accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations. Gains or losses on the disposal of discontinued operations, including any adjustments to reflect the fair value less costs to sell of net assets, are recognized in the period in which the disposal occurs.
The Company assesses whether any of the assets or liabilities of the discontinued operation are impaired at the date of classification and recognizes any required adjustments in the condensed consolidated financial statements. Subsequent changes in estimates or outcomes related to discontinued operations are recognized in the period of the change.
New Accounting Standards
Recently adopted
In December 2023, the FASB issued ASU 2023-08, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (“ASU 2023-08”), which establishes accounting guidance for crypto assets that meet specified criteria, including that they are (i) intangible, (ii) created or reside on a distributed ledger, (iii) secured through cryptography, and (iv) fungible. The crypto assets, or digital assets, acquired by the Company during the three months ended December 31, 2025 meet these criteria. ASU 2023-08 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company adopted the standard beginning with the three months ended December 31, 2025. As a result of the adoption, the Company did not have a cumulative-effect adjustment as the Company did not have any digital assets prior to January 1, 2025. In the three and nine months ended June 30, 2026, the digital assets are recognized at fair value.
Recently issued accounting pronouncements not yet effective
In November 2024, the FASB issued Accounting Standards Update 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40): update required disclosure of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026. The Company has not early adopted this standard. The Company is currently evaluating the impact of the adoption of this amendment.
In July 2025, the Financial Accounting Standards Board issued Accounting Standards Update 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets. The objective of this update is to reduce the cost and complexity of applying the current expected credit loss model (CECL) to short-term accounts receivable and contract assets. ASU 2025-05 addresses these challenges by introducing a practical expedient that allows entities to assume that current conditions as of the balance sheet date do not change over the remaining life of the asset. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that adoption of this amendment will have a material impact on its condensed consolidated financial statements and disclosures.
| 18 |
Note 2 – Asset acquisition
On June 16, 2026, the Company completed a transaction with EMJ Crypto Technologies Inc., a corporation organized under the laws of Ontario, Canada (“EMJC”), pursuant to a Share Exchange and Asset Transfer Agreement, dated December 16, 2025, and amended on March 11, 2026 and June 17, 2026 (as amended, the “Transfer Agreement”), by and among the Company, EMJC, CCC Crypto Corp., a Delaware corporation (“CCC Crypto”), 1001440571 Ontario Inc., a corporation organized under the laws of Ontario, Canada and an indirect wholly-owned subsidiary of the Company (“ExchangeCo”), and the other parties thereto (the “Transaction”).
At
the closing of the Transaction (the “Closing”), the Company acquired
As
consideration, the Company issued to EMJC and certain other parties to the Transaction an aggregate of
The shares of Common Stock issued at the Closing, and the shares of Common Stock issuable upon the exchange or exercise of the Exchangeable Shares and Pre-Funded Warrants issued at the Closing, have been registered under the Securities Act of 1933, as amended (the “Securities Act”) in a Registration Statement on Form S-4 declared effective by the SEC on May 7, 2026.
In connection with the Closing, the Company changed its name to “SRX Global Inc.” and entered into a services agreement with Eric M. Jackson, the founder of EMJX, pursuant to which Mr. Jackson provides services related to the operation of the EMJX platform and serves as President of EMJX and Head of Asset Management.
The Transaction was accounted for as an asset acquisition in accordance with ASC 805-50, Business Combinations — Related Issues, under which the cost of the asset acquisition was allocated to the assets acquired and liabilities assumed based on their relative fair values as of the Closing date.
The Transaction involved the acquisition of assets from EMJC and CCC Crypto, which have been combined and treated as a single asset group (“EMJX”) for purposes of the purchase price allocation presented herein.
As a result, no goodwill was recognized, and the excess of the purchase price over the fair value of identifiable net assets acquired was allocated to the identifiable assets acquired on a relative fair value basis.
The
fair value of the equity consideration transferred in the Transaction was $
The
following table presents the summary allocation of the $
| June 16, 2026 | ||||
| Common stock | $ | |||
| Cash | $ | |||
| Total consideration | $ | |||
| Intangible assets | ||||
| Total assets acquired | $ | |||
| Net assets acquired | $ | |||
Refer to Note 9 – Intangible assets, for further discussion of the useful life, amortization method, and carrying value of the intellectual property – developed technology asset acquired in the Transaction.
| 19 |
Note 3 – Revenue
The Company records revenue net of discounts, which primarily consist of trade promotions, certain customer allowances and early pay discounts.
Revenue channels
The
Company groups its revenue channels into
Information about the Company’s net sales by revenue channel is as follows (in thousands):
| Three months ended June 30, | Nine months ended June 30, | |||||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||||||
| Digital (1) | $ | % | $ | % | $ | % | $ | % | ||||||||||||||||||||||||
| International (2) | % | % | % | % | ||||||||||||||||||||||||||||
| Brick & Mortar (3) | % | % | % | % | ||||||||||||||||||||||||||||
| Net Sales (4) | $ | % | $ | % | $ | % | $ | % | ||||||||||||||||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
Note 4 - Inventories
Inventories are summarized as follows (in thousands):
| June 30, 2026 | September 30, 2025 | |||||||
| Food, treats and supplements | $ | $ | ||||||
| Inventory packaging and supplies | ||||||||
| Total | $ | $ | ||||||
Note 5 – Digital assets
The Company holds certain digital assets that meet the definition of crypto assets under with ASC 350, Intangibles—Goodwill and Other, as amended by ASU 2023-08, Accounting for and Disclosure of Crypto Assets. Under ASU 2023-08, qualifying crypto assets are required to be measured at fair value in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in net income in each reporting period.
To qualify for this guidance, a crypto asset must be (i) intangible in nature, (ii) created or reside on a distributed ledger based on blockchain or similar technology, (iii) secured through cryptography, (iv) fungible, and (v) not provide the asset holder with enforceable rights to underlying goods, services, or other assets. All digital assets held by the Company during the period met these criteria and are accounted for in accordance with ASU 2023-08.
As of June 30, 2026, the Company held the following crypto assets (dollars in thousands):
| Quantity | Cost Basis | Market Value | ||||||||||
| Ethereum | $ | $ | ||||||||||
| 20 |
The Company measures its digital assets at fair value at each reporting period in accordance with ASC 820. Because active markets exist for the Company’s digital assets, and unadjusted quoted prices are available, the Company uses Level 1 inputs for valuation. The Company determines fair value based on quoted prices on Coinbase exchange, which the Company has identified as its principal market for its digital assets. Digital assets are recorded at fair value on the condensed consolidated balance sheet within Investments in digital assets and changes in fair value are recognized as incurred and recorded in change in fair value of digital assets within the condensed consolidated statements of operations.
The following table summarizes the Company’s digital asset purchases and unrealized gains (losses) for the period (dollars in thousands):
Three Months Ended June 30, 2026 | Nine Months Ended June 30, 2026 | |||||||
| Beginning balance of digital assets | $ | $ | ||||||
| Purchases | ||||||||
| Proceeds from sale | ( | ) | ( | ) | ||||
| Change in fair value | ( | ) | ( | ) | ||||
| Ending balance of digital assets | $ | $ | ||||||
A portion of the Company’s assets is concentrated in digital assets. The holding of digital assets exposes the Company to significant legal, commercial, regulatory, and technological uncertainties. Crypto asset markets have historically exhibited extreme price volatility. A substantial decline in the fair value of these assets could adversely affect the Company’s financial condition and results of operations.
Digital assets do not generate cash flows and incur custodial fees, transaction fees, and other costs. The Company also faces counterparty risk related to its digital asset custodian, and cybersecurity risk, including the risk of loss due to hacking, security breaches, technological failures, and other cyber threats associated with blockchain networks and digital wallets.
The Company’s digital assets are secured by private cryptographic keys. Loss, theft, or destruction of these keys may result in the permanent loss of some or all of the Company’s digital assets, which could materially and adversely impact the Company’s financial condition and operating results.
Additionally, the regulatory environment for digital assets continues to evolve. Future legislative or regulatory actions, changes in accounting standards, or shifts in enforcement priorities could impact the Company’s ability to hold, transfer, or dispose of digital assets, or could require changes to financial reporting or compliance practices.
Note 6 – Derivatives and hedging activities
The
Company enters into exchange-traded option contracts for investment and risk management purposes. As of June 30, 2026, the Company had
no open derivative position, and the aggregate net fair value of derivative instruments was
The
Company sells these options to gain and enhance exposure to the underlying assets. Because these instruments do not qualify for hedge
accounting, changes in their fair value are recognized directly in earnings. For the three and nine months ended June 30, 2026, the Company
recognized net gains of approximately $
| 21 |
The table below presents the fair value and quantity of the Company’s derivative financial instruments, included within accrued liabilities on the condensed consolidated balance sheet as of June 30, 2026 and September 30, 2025 (dollars in thousands):
| As of June 30, 2026 | As of September 30, 2025 | |||||||||||||||
| Fair Value | Number of Contracts | Fair Value | Number of Contracts | |||||||||||||
| Equity contracts | $ | $ | ||||||||||||||
| Commodities contracts | ||||||||||||||||
| Interest rate products | ||||||||||||||||
| Crypto currency contracts | ||||||||||||||||
| Total derivatives not designated as hedging instruments | $ | $ | ||||||||||||||
The table below presents gains (losses) recognized in the condensed consolidated statement of operations related to the Company’s derivative financial instruments (dollars in thousands):
Three Months Ended June 30, | Nine Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Equity contracts | $ | $ | ||||||||||||||
| Commodities contracts | ||||||||||||||||
| Interest rate products | ||||||||||||||||
| Crypto currency contracts | ||||||||||||||||
| Total | $ | $ | ||||||||||||||
Note 7 – Notes receivable
March 2026 Convertible Note Receivable
On
March 12, 2026, the Company entered into a convertible promissory note agreement in an arm’s-length transaction pursuant to which
the Company purchased a convertible note receivable with a gross principal amount of $
The
Convertible Note Receivable includes a voluntary conversion feature permitting the holder, at its option, to convert all or a portion
of the outstanding principal and accrued interest under the note into ordinary shares of the issuer at a conversion price equal to the
lower of (i) the fair market value of the issuer’s ordinary shares as determined by an independent appraisal firm agreeable to
the holder or (ii) a valuation derived from a negotiated enterprise value of $
On June 9, 2026, the Company sold the March 2026 Convertible Note Receivable to a third-party in an arm’s-length transaction for cash consideration equal to the outstanding principal amount of the note plus reimbursement of origination fees incurred by the Company at issuance. Separately, the Company received payment of all accrued and unpaid interest on the note from the issuer through the sale date. No other assets of the Company were transferred as part of this transaction.
Upon
the sale, the Company derecognized the March 2026 Convertible Note Receivable, along with the associated unaccreted OID, from its condensed
consolidated balance sheet, as the transfer met the criteria for sales under ASC 860, including surrender of control over the note. The
excess of the consideration received over the note’s carrying value resulted in a gain on sale of approximately $
For
the period from issuance through the sale date, the Company recognized approximately $
Following
the sale, the Company has no continuing involvement with, or remaining exposure to, the March 2026 Convertible Note Receivable, and
| 22 |
April 2026 Convertible Note Receivable
On
April 24, 2026, the Company purchased a convertible promissory note with a principal amount of $
The April 2026 Note Receivable contains provisions that permit or require conversion into equity securities of the borrower upon certain financing, listing, maturity or corporate transaction events. The Company evaluated the embedded conversion and settlement features under ASC 815-15 and determined that bifurcation was not required. The Company did not elect the fair value option under ASC 825 and subsequently measures the note receivable at amortized cost.
As
of June 30, 2026, the April 2026 Note Receivable had a carrying value of $
May 2026 Loan Agreement
On
May 27, 2026, the Company entered into a loan agreement in an arm’s-length transaction pursuant to which the Company, as lender,
advanced a loan with a gross principal amount of approximately $
The
loan was issued with an original issue discount (“OID”) consisting of approximately $
The
Company accounts for the May 2026 Loan Agreement at amortized cost, net of the unaccreted OID. As of June 30, 2026, the note receivable
had a carrying value of $
Because
the loan is denominated in British pounds sterling and the Company’s functional currency is the U.S. dollar, the note receivable
and related accrued interest are remeasured into U.S. dollars at the spot exchange rate as of each balance sheet date in accordance with
ASC 830-20, with the resulting gain or loss recognized in earnings. For the three months ended June 30, 2026, the Company recognized
interest income of $
The
Company evaluated the note receivable for expected credit losses in accordance with ASC 326 and determined that
May 2026 Convertible Note Receivable
On
May 28, 2026, the Company entered into a convertible grid promissory note agreement in an arm’s-length transaction to pursuant
to which the Company, as lender, advanced approximately $
On
June 23, 2026, the Company and the borrower amended and restated the Original Note in its entirety (as amended, the “May 2026 Note
Receivable”), pursuant to which the Company advanced an additional approximately $
The May 2026 Note Receivable includes a conversion feature permitting the Company to convert outstanding principal and accrued interest into shares of the borrower’s common stock at a conversion price equal to the lower of a fixed floor price or a discount to the borrower’s recent trading price, with the number of shares and, under certain circumstances, related cash settlement amounts varying based on the borrower’s future stock price. The Company evaluated the embedded features under ASC 815-15 and concluded that the conversion feature requires bifurcation from the debt host. Accordingly, the Company accounts for the conversion feature and related equity-linked settlement provisions as a single compound embedded derivative asset. The derivative asset is measured at fair value upon initial recognition and subsequently at each reporting date, with changes in fair value recognized in earnings. The debt host is initially measured as the residual after allocation of the derivative asset and is subsequently measured at amortized cost. The resulting discount, consisting of the contractual OID and the amount attributable to the initial derivative allocation, is accreted to interest income over the contractual term using the effective interest method.
| 23 |
As
of June 30, 2026, the note receivable consisted of a debt host with a carrying value of $
The Company estimated the fair value of the derivative asset using a probability-weighted valuation methodology that considered the potential settlement outcomes and related economic payoff of the embedded features. The embedded features are valued together and presented as a single compound derivative asset.
The Company evaluated the debt host component of the note receivable for expected credit losses in accordance with ASC 326. As of June 30, 2026, based on consideration of the borrower’s financial condition and other relevant factors, the Company determined that no allowance for credit losses was required.
Note 8 - Fixed assets
Fixed assets consist of the following (in thousands):
| Estimated Useful Life | June 30, 2026 | September 30, 2025 | ||||||||
| Equipment | $ | $ | ||||||||
| Furniture and fixtures | ||||||||||
| Computer software | ||||||||||
| Total property and equipment | ||||||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||||
| Net property and equipment | $ | $ | ||||||||
During
the three months ended March 31, 2026, the Company recorded a non-cash fixed asset balance adjustment of approximately $
Depreciation
expense was $
Note 9 – Intangible assets
Intangible assets consisted of the following (in thousands):
| June 30, 2026 | ||||
| Intellectual property - developed technology | $ | |||
On
June 16, 2026, the Company acquired developed technology for total consideration of $
The developed technology represents EMJX’s proprietary AI-driven digital asset treasury operating system, designed to manage multi-asset digital holdings using quantitative models, artificial intelligence, and systematic risk controls. The Company determined that the developed technology has an indefinite useful life, based on the absence of an expiring license, patent, or other contractual term underlying the technology’s value, the Company’s intent and ability to continue developing, retraining, and enhancing the technology, and the absence of an identifiable technological obsolescence horizon.
| 24 |
Note 10 – Debt
ELOC Commitment Note
On
October 28, 2025, the Company issued a convertible promissory note related to its common stock purchase agreement entered into in July
2025 with an aggregate principal amount of $
The
accredited investor of the ELOC Commitment Note held the option, at its sole discretion and upon timely notice, to convert all or a portion
of the unpaid principal and accrued interest into the Company’s common stock at a conversion price equal to the lesser of
During
the three months ended June 30, 2026, the accredited investor converted the entire $
Prior
to completion of the final conversion, the Company and the accredited investor agreed that the accredited investor would waive its contractual
right to all accrued interest under the ELOC Commitment Note, which agreement was memorialized in a First Amendment to the ELOC Commitment
Note executed on June 30, 2026. Management concluded that, because the substance of the waiver was agreed prior to final settlement of
the ELOC Commitment Note, it should be accounted for under ASC 470-50 as part of the modification and settlement of the ELOC Commitment
Note. The Company derecognized the accrued contractual interest liability and the remaining derivative liability, net of the unamortized
debt discount, and recognized a resulting gain on debt modification of approximately $
During
the three months ended June 30, 2026, the Company issued approximately million shares of common stock pursuant to drawdowns under
the ELOC Purchase Agreement, generating aggregate cash proceeds of $
The table below summarizes the components used to determine the initial carrying amount of the ELOC Commitment Note as of October 28, 2025 (in thousands):
| Amount | ||||
| Principal amount | $ | |||
| Less: original issue discount | ( | ) | ||
| Add: fair value of derivative liabilities | ||||
| Initial carrying amount of the ELOC Commitment Note at October 28, 2025 | $ | |||
The carrying amount of the ELOC Commitment Note as of December 31, 2025 is summarized below (in thousands):
| Amount | ||||
| Initial carrying amount | $ | |||
| Add: amortization of debt discount | ||||
| Add: change in fair value of derivative liabilities | ||||
| Carrying amount of the ELOC Commitment Note at December 31, 2025 | $ | |||
The carrying amount of the ELOC Commitment Note as of March 31, 2026 is summarized below (in thousands):
| Amount | ||||
| Initial carrying amount | $ | |||
| Add: amortization of debt discount | ||||
| Add: change in fair value of derivative liabilities | ||||
| Carrying amount of the ELOC Commitment Note at March 31, 2026 | $ | |||
| 25 |
The carrying amount of the ELOC Commitment Note as of June 30, 2026 is summarized below (in thousands):
| Amount | ||||
| Initial carrying amount | $ | |||
| Add: amortization of debt discount | ||||
| Add: change in fair value of derivative liabilities | ( | ) | ||
| Less: conversion of ELOC Commitment Note into common stock | ( | ) | ||
| Carrying amount of the ELOC Commitment Note at June 30, 2026 | $ | |||
July 2025 convertible notes
On
July 7, 2025, the Company issued senior secured convertible notes with an aggregate principal amount of $
The
primary conversion feature within the July 2025 Notes provides the holders the right to convert the principal amount into the Company’s
common stock at a fixed conversion price of $
The Company evaluated this conversion feature under ASC 815-40 and concluded that it meets the criteria for equity classification. Accordingly, the conversion feature was not bifurcated from the host debt instrument and no derivative liability was recognized. In addition, because the July 2025 Notes were not issued at a substantial premium, no beneficial conversion feature was recorded under ASC 470-20.
Certain
other provisions contained within the July 2025 Notes allow the holder, upon the occurrence of defined triggering events, to convert
the debt into common stock at
The table below summarizes the components used to determine the initial carrying amount of the July 2025 Notes as of July 7, 2025 (in thousands):
| Amount | ||||
| Principal amount | $ | |||
| Less: original issue discount | ( | ) | ||
| Less: issuance costs | ( | ) | ||
| Add: fair value of derivative liabilities | ||||
| Initial carrying amount of the July 2025 Notes at July 7, 2025 | $ | |||
The carrying amount of the July 2025 Notes as of September 30, 2025 is summarized below (in thousands):
| Amount | ||||
| Initial carrying amount | $ | |||
| Less: cash payments on convertible debt | ( | ) | ||
| Add: amortization of debt discount and issuance costs | ||||
| Add: change in fair value of derivative liabilities | ||||
| Carrying amount of the July 2025 Notes at September 30, 2025 | $ | |||
| 26 |
The carrying amount of the July 2025 Notes as of June 30, 2026 is summarized below (in thousands):
| Amount | ||||
| Initial carrying amount | $ | |||
| Less: settlement of July 2025 Notes | ( | ) | ||
| Carrying amount of the July 2025 Notes at December 31, 2025 | $ | |||
In
connection with issuing the July 2025 Notes, the Company executed a Securities Purchase Agreement that also included
After
deducting the original issue discount, issuance costs, fair value of warrants, and the fair value of derivative liabilities, the Company
received net proceeds of approximately $
In
October 2025, the Company settled its outstanding July 2025 Notes with the note holders through a settlement agreement, under which the
notes, along with all accrued interest and related derivative liabilities, were fully settled and extinguished. The related $
Note 11 – Fair value measurements
Fair value hierarchy Levels 1 to 3 are based on the degree to which the fair value is observable:
Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3 fair value measurement are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).
The Company has assessed that the fair value of cash and cash equivalents, restricted cash, short-term investments, trade and other receivables, notes receivable, digital assets, investment in equity securities, derivative assets and liabilities, and trade and other payables approximate their carrying amounts largely due to the short-term maturities of these instruments.
The carrying amount of the Company’s borrowings are considered to be the same as their fair values, as the terms of the Company’s borrowings are considered to be consistent with the commercial terms prevalent for similar loans. The Company has classified its short-term investments, digital assets and marketable equity securities as Level 1 financial instruments due to the use of quoted prices in active markets for identical assets. The Company has classified its derivative liabilities and non-marketable equity securities as Level 3 financial instruments due to the use of unobservable inputs in their valuations.
The Company has no financial instruments classified as Level 2.
| 27 |
Financial risk management
The Company’s activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (primarily interest rate risk). Risk management is carried out by the Company by identifying and evaluating the financial risks inherent within its operations. The Company’s overall risk management activities seek to minimize potential adverse effects on the Company’s financial performance.
Liquidity risk
The Company is exposed to liquidity risk related to its financial liabilities, including trade payables. Management monitors liquidity through cash flow forecasts and maintains access to credit facilities.
The following table summarizes the contractual maturities of the Company’s financial liabilities on an undiscounted basis:
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 and over | Total | |||||||||||||||||||
| Trade and other payables | ||||||||||||||||||||||||
| Total | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
As of June 30, 2026 and September 30, 2025, the Company has no financial instruments requiring fair value measurement disclosures that differ from their carrying amounts; accordingly.
Note 12 – Commitments and contingencies
The Company has manufacturing agreements with its vendors that provides for the company to make its commercial best efforts to purchase minimum quantities in the ordinary course of business. The Company had no material purchase obligations as of June 30, 2026 or September 30, 2025.
The Company may be involved in legal proceedings, claims, and regulatory, tax, or government inquiries and investigations that arise in the ordinary course of business resulting in loss contingencies. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability. Legal costs such as outside counsel fees and expenses are charged to expense in the period incurred and are recorded in SG&A expenses. The Company does not accrue for contingent losses that are considered to be reasonably possible, but not probable; however, the Company discloses the range of such reasonably possible losses. Loss contingencies considered remote are generally not disclosed.
Litigation is subject to numerous uncertainties and the outcome of individual claims and contingencies is not predictable. It is possible that some legal matters for which reserves have or have not been established could result in an unfavorable outcome for the Company and any such unfavorable outcome could be of a material nature or have a material adverse effect on the Company’s condensed consolidated financial condition, results of operations and cash flows. Management is not aware of any claims or lawsuits that may have a material adverse effect on the condensed consolidated financial position or results of operations of the Company.
Discontinued operations
Certain legal matters, claims, and purchase obligations related to SRx Canada, which is classified as discontinued operations, are presented in Note 22 – Discontinued operations. These matters are subject to the same accounting policies as described above. Management does not expect any such matters to have a material impact on the results of continuing operations; however, they could affect the financial results of the discontinued operations segment.
| 28 |
Note 13 – Preferred stock, warrants and other equity
Series B Convertible Preferred Stock and Warrants
In
March 2026, the Company entered into a securities purchase agreement to issue Series B convertible preferred stock and accompanying
warrants for aggregate proceeds of up to $
The
Series B convertible preferred stock is convertible into shares of Company’s common stock at an initial conversion price of $
The Company accounted for the Series B convertible preferred stock and warrants as equity-classified instruments and allocated proceeds between the instruments using a relative fair value methodology. The warrants were valued using a Black-Scholes valuation model. As of June 30, 2026, all of Series B convertible preferred stock and accompanying warrants remain outstanding.
Series A Convertible Preferred Stock and Warrants
In
October 2025, the Company entered into a securities purchase agreement with accredited investors to issue Series A convertible
preferred stock and warrants for aggregate proceeds of up to $
During the three months ended March 31, 2026, an aggregate of shares of the Company’s Series A convertible preferred stock were converted into shares of the Company’s common stock. In connection with these non-cash conversions, the Company issued shares of common stock at an average conversion price of $ per share. The conversions were accounted for as equity transactions, and no gain or loss was recognized upon conversion.
On
February 11, 2026, the Company redeemed shares of Series A convertible preferred stock, representing all of
the issued and outstanding shares of Series A Preferred Stock, for an aggregate redemption price of approximately $
Cashless Exercises of Series A Warrants
In March 2026, an aggregate of of outstanding Series A warrants were exercised on a cashless basis, resulting in the issuance of approximately shares of the Company’s common stock.
In the three months ended June 30, 2026, an aggregate of outstanding Series A warrants were exercised on a cashless basis, resulting in the issuance of approximately shares of the Company’s common stock. Additionally, in the three months ended June 30, 2026, an aggregate of of outstanding Series A warrants were exercised on a cash basis, resulting in the issuance of approximately shares of the Company’s common stock.
As
of June 30, 2026, an aggregate of
The cashless warrant exercises were accounted for as equity transactions. The issuance of common stock was recorded through a reclassification within stockholders’ equity, with a corresponding reduction to the carrying amount of the warrants. No cash proceeds were received by the Company in connection with these exercises.
| 29 |
Equity Warrants
The Company has issued warrants in connection with various equity and debt financing transactions. The fair value of warrants issued was determined using valuation methodologies including the Black-Scholes option pricing model, utilizing market price of the Company’s common stock on the issuance date and other appropriate valuation assumptions. All unexercised warrants outstanding at SRx Canada expired prior to the April 2025 merger.
The following table summarizes the continuity of the Company’s outstanding warrants as of June 30, 2026:
Warrants # | Weighted Average Exercise Price | |||||||
| Warrants outstanding on September 30, 2025 | $ | |||||||
| Issued | ||||||||
| Exercised | ( | ) | ||||||
| Expired | ( | ) | ||||||
| Warrants outstanding as of December 31, 2025 | $ | |||||||
| Issued | ||||||||
| Exercised | ( | ) | ||||||
| Expired | ||||||||
| Warrants outstanding as of March 31, 2026 | $ | |||||||
| Issued | ||||||||
| Exercised | ( | ) | ||||||
| Expired | ||||||||
| Warrants outstanding as of June 30, 2026 | $ | |||||||
July 2025 Warrants
On
July 7, 2025, in connection with the convertible debt financing described in Note 10 – Debt, the Company issued
In
connection with the financing, the Company also entered into a registration rights agreement requiring it to register for resale the
common shares issuable upon conversion of the notes and exercise of the warrants. As of June 30, 2026,
Pre-Funded and Representative Warrants
On
April 24, 2025, the Company issued to a single investor a combination of
As
of June 30, 2026, the Company had
Exchangeable Shares
As of June 30, 2026, the Company had exchangeable shares outstanding related to the EMJX acquisition and exchangeable shares outstanding related to its discontinued operations.
Common Stock Repurchase
On
February 3, 2026, the Company entered into a securities purchase agreement with a shareholder pursuant to which the Company
repurchased shares of common stock for an aggregate purchase price of $
| 30 |
Note 14 – Investments in equity securities
Marketable Equity Securities
On
March 23, 2026, the Company purchased shares of common stock of Smartkem, Inc., a publicly traded company, for
an aggregate purchase price of approximately $
As
of June 30, 2026, the fair value of the investment was approximately $
The fair value of the Smartkem, Inc. equity securities was determined based on observable market prices in active markets and is classified within Level 1 of the fair value hierarchy.
Non-marketable Equity Securities
Smartkem Investment
On
March 30, 2026, the Company made an investment in Smartkem, Inc. (“Smartkem”) through the purchase of
convertible preferred stock and
On
June 18, 2026, pursuant to an additional closing under the same Securities Purchase Agreement, as amended, the Company purchased an additional
shares of Series A Convertible Preferred Stock and warrants to purchase up to shares of common stock of Smartkem for
an aggregate purchase price of approximately $
The Company does not have a controlling financial interest in, or the ability to exercise significant influence over, Smartkem. The Company accounts for its investment in Smartkem, including the preferred stock and warrants, as an equity security under ASC 321 and has elected to apply the measurement alternative, under which the investment is carried at cost, less any impairment, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.
As
of June 30, 2026, the aggregate carrying value of the Company’s investment in Smartkem was $
Astro Investment
On
April 16, 2026, the Company through its wholly owned subsidiary, Halo, invested $
The Company accounts for its investment in the Fund as an equity security without a readily determinable fair value under ASC 321. The Company has elected the measurement alternative under which the investment is carried at cost, less any impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.
As
of June 30, 2026, the carrying amount of the investment was $
SAFE Investment
On
June 1, 2026, the Company, through its wholly owned subsidiary, Halo, entered into a Simple Agreement for Future Equity (“SAFE”)
pursuant to which Halo agreed to invest up to an aggregate of $
The Company accounts for its investment in the SAFE as an equity security without a readily determinable fair value under ASC 321. The Company has elected the measurement alternative, under which the investment is carried at cost, less any impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.
As
of June 30, 2026, the carrying amount of the investment was approximately $
| 31 |
In connection with the Merger completed on April 24, 2025, the Company adopted and continues to maintain the Legal Acquirer’s Amended and Restated 2019 Incentive Award Plan (the “Amended 2019 Plan”), which provides for the grant of equity-based awards, including stock options, restricted stock units (“RSUs”), restricted stock awards, and other stock-based awards, to employees, directors and consultants. As of June 30, 2026, an aggregate of shares of the Company’s common stock were authorized for issuance under the Amended 2019 Plan, of which shares remained available for future grants.
Awards are measured at grant date fair value in accordance with ASC 718, and compensation expense is recognized over the requisite service period using the graded attribution method.
During the three and nine months ended June 30, 2026, the Company recognized and $ million, respectively, of share-based compensation expense related to awards granted under the Amended 2019 Plan.
RSUs # | ||||
| RSUs outstanding on September 30, 2025 | ||||
| Issued | ||||
| Vested | ( | ) | ||
| Forfeited and cancelled | ||||
| RSUs outstanding on December 31, 2025 | ||||
| Issued | ||||
| Vested | ||||
| Forfeited and cancelled | ||||
| RSUs outstanding on March 31, 2026 | ||||
| Issued | ||||
| Vested | ||||
| Forfeited and cancelled | ||||
| RSUs outstanding on June 30, 2026 | ||||
| 32 |
Stock options
The fair value of stock options granted is estimated on the grant date using the Black-Scholes option pricing model. The determination of fair value using the Black-Scholes model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, expected term, risk-free interest rates and expected dividends.
Options # | Weighted Average Exercise Price | |||||||
| Options outstanding on September 30, 2025 | $ | |||||||
| Issued | ||||||||
| Expired | ||||||||
| Forfeited and cancelled | ||||||||
| Options outstanding on December 31, 2025 | $ | |||||||
| Issued | ||||||||
| Expired | ||||||||
| Forfeited and cancelled | ( | ) | ||||||
| Options outstanding on March 31, 2026 | $ | |||||||
| Issued | ||||||||
| Expired | ||||||||
| Forfeited and cancelled | ||||||||
| Options outstanding on June 30, 2026 | $ | |||||||
Shares issued to related parties
For the three months ended December 31, 2025, the Company issued an aggregate of shares of restricted common stock to certain directors, officers, employees, and former employees of the Company as performance or service-based compensation. No shares of restricted common stock were issued during the three months ended June 30, 2026.
On October 1, 2025, the Company issued shares of restricted common stock to certain directors at a weighted average grant price of $ per share. These awards were immediately vested.
On November 10, 2025, the Company issued shares of restricted common stock to certain directors at a weighted average grant price of $ per share. These awards were immediately vested.
On December 3, 2025, the Company issued shares of restricted common stock to certain directors, officers, and employees as performance bonus compensation. The restricted stock awards were immediately vested, with a weighted average grant price of $ per share.
Additionally, between October and December 2025, the Company issued shares of common stock pursuant to the retraction of shareholders’ exchangeable shares, which converted into shares of common stock. These shareholders were former employees and shareholders of SRx Canada that initially received exchangeable shares in connection with the Merger.
The fair value of these awards was determined at the grant date and recognized as compensation expense in the condensed consolidated statement of operations in accordance with ASC 718.
Note 16 – Employee benefit plans
The
Company has a qualified defined contribution 401(k) plan, which covers substantially all of its employees. Participants are entitled
to make pre-tax and/or Roth post-tax contributions up to the annual maximums established by the Internal Revenue Service. The Company
matches participant contributions pursuant to the terms of the plan, which contributions are limited to a percentage of the participant’s
eligible compensation. The Company made contributions related to the plan and recognized expense of approximately $
Note 17 – Related party transactions
In
connection with the asset acquisition described in Note 2 – Asset acquisition, the Company transferred equity consideration with
a fair value of approximately $
Mr.
Jackson is compensated for his services to the Company pursuant to a services agreement, under which he received an upfront payment
of $
| 33 |
Fees and compensation
For
the three and nine months ended June 30, 2026, the Company’s continuing operations incurred approximately $
During the three and nine months ended June 30, 2026, the Company issued to its directors and executive officers an aggregate of and $ million, respectively, in share-based compensation, presented within selling, general and administrative expenses in the condensed consolidated statements of operations.
During
the three and nine months ended June 30, 2026, the Company paid its executive officers an aggregate of $
July 2025 notes and Series A participation
As
of September 30, 2025, the Company had outstanding convertible promissory notes held by certain members of the Board of Directors totaling
approximately $
In
October 2025, the outstanding principal and accrued interest under these notes were exchanged and extinguished in connection with the
Company’s Series A financing transaction. In connection with the Series A financing, related party participants purchased an aggregate
of shares of Series A convertible preferred stock and received warrants exercisable for an aggregate of
On
February 11, 2026, the Company redeemed the Series A convertible preferred stock held by these related party participants for aggregate
cash consideration of approximately $
During
the three months ended March 31, 2026, related party holders exercised an aggregate of
Series B participation
Certain
directors and executive officers participated in the Company’s Series B financing transaction, which initially closed on March
16, 2026, on terms equivalent to those offered to unaffiliated investors. Such related party participants purchased an aggregate of
shares of Series B convertible preferred stock and received warrants exercisable for an aggregate of
Governance and controls
As
of June 30, 2026 and September 30, 2025 there were
The Company has adopted a formal Related Party Transaction Policy to ensure appropriate oversight of any future transactions with related parties. All related party transactions are subject to review and approval by the Audit Committee of the Board of Directors, in accordance with SEC Regulation S-K Item 404 and the Company’s internal policies.
Note 18 – Income taxes
For
the three and nine months ended June 30, 2026, the Company recorded an income tax provision of less than $
The income tax provision for the quarter primarily relates to state minimum and franchise taxes, as well as discrete items recorded during the period. The Company will continue to assess the realizability of its deferred tax assets each reporting period based on available positive and negative evidence.
| 34 |
Note 19 – Segment information
As
of June 30, 2026, the Company reports
The Consumer Products segment includes the legacy Halo pet food business, consisting of premium pet products such as dry kibble, wet food, freeze-dried raw food, treats, and toppers for dogs and cats. This segment operates across various sales channels and represents the Company’s ongoing legacy business.
The EMJX segment includes the Company’s digital-asset treasury management platform, acquired in the Transaction on June 16, 2026, which manages a multi-asset digital holdings strategy governing how capital is allocated, hedged, and reinvested across market cycles. EMJX became a reportable segment of the Company upon the Closing of the Transaction, and accordingly, the Company’s results for the EMJX segment include activity only from June 16, 2026.
The former Health Solutions segment, which encompassed the Company’s pharmacy network operations in Canada, has been classified as discontinued operations as of June 30, 2026 and September 30, 2025, and accordingly, its results and related assets and liabilities are reported separately in the financial statements.
The Company’s Chief Operating Decision Maker (“CODM”), the Board of Directors, evaluates the Company’s financial performance of, and allocates resources to, the Company’s two reportable segments, Consumer Products and EMJX, separately, given the distinct nature of their products, services, customers, and economic characteristics. Prior to the Closing of the Transaction, and prior to the discontinuation of Health Solutions, the CODM evaluated the Company’s financial performance based on the Health Solutions and Consumer Products segments.
For the three months ended June 30, 2026, segment financial information for continuing operations relates to the Consumer Products segment, which was acquired through a business combination on April 25, 2025, and the EMJX segment, which reflects results only from the Closing date of June 16, 2026 through June 30, 2026. EMJX had no reportable revenues, operating expenses or other segment results during the period from June 16, 2026 through June 30, 2026 and, accordingly, no separate amounts are presented for EMJX in the table below. There are no comparative results for the EMJX segment for periods prior to the Closing because EMJX became a segment of the Company upon consummation of the Transaction.
The following table summarizes revenues, operating loss, and net loss attributable to the Consumer Products segment for the three and nine months ended June 30, 2026 and 2025 (in thousands):
| Three months ended June 30, | Nine months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | $ | $ | $ | ||||||||||||
| Cost of goods sold: | ||||||||||||||||
| Direct | ||||||||||||||||
| Indirect | ||||||||||||||||
| Total cost of goods sold | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Segment expenses: | ||||||||||||||||
| Discretionary marketing | ||||||||||||||||
| Outbound freight | ||||||||||||||||
| Other segment expenses (a) | ||||||||||||||||
| Total segment expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expense (income): | ||||||||||||||||
| Interest income (expense), net | ( | ) | ( | ) | ||||||||||||
| Loss on extinguishment of debt | ( | ) | ||||||||||||||
| Change in fair value of digital assets | ||||||||||||||||
| Change in fair value of equity securities | ( | ) | ||||||||||||||
| Change in fair value of derivative liabilities | ( | ) | ( | ) | ||||||||||||
| Bargain purchase gain | ( | ) | ( | ) | ||||||||||||
| Other income, net | ( | ) | ( | ) | ||||||||||||
| Total other expense, net | ( | ) | ( | ) | ||||||||||||
| Net loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| (a) |
The accounting policies of the segment are consistent with those described in Note 1 – Nature of business and summary of significant accounting policies.
Geographic Information
Revenue by geography is based on where the customer is based. Summary financial data attributable to various geographic regions for the periods indicated is as follows:
| Three Months Ended June 30, | Nine Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| United States | $ | $ | $ | $ | ||||||||||||
| Canada | ||||||||||||||||
| Asia | ||||||||||||||||
| Central America | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| 35 |
Note 20 – Concentrations
Major suppliers
The
Company sourced approximately
Major customers
Accounts
receivable from three customers represented
Credit risk
As of June 30, 2026 and September 30, 2025, the Company’s cash and cash equivalents were deposited in accounts at several financial institutions and may maintain some balances in excess of federally insured limits. The Company maintains its cash and cash equivalents with high-quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses historically in these accounts and believes it is not exposed to significant credit risk in its cash and cash equivalents.
The Company is also exposed to credit risk on its trade accounts receivable. In evaluating expected credit losses under ASC 326, the Company considers historical collection experience, the credit quality of its customers, and current economic conditions. Historically, the Company has experienced minimal bad debts and high collection rates, and as such, expected credit losses on accounts receivable are considered low and the related allowance is not material.
The Company presents net loss per share on a basic and diluted basis for the three months ended June 30, 2026 and 2025. Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding (“WASO”) during the period. For the three months ended June 30, 2026 and 2025, the Company’s basic and diluted net loss per share attributable to common stockholders are the same as the Company generated a net loss.
For the three and nine months ended June 30, 2026, the Company’s basic and diluted net loss per share attributable to common stockholders are the same as the Company generated a net loss and common stock equivalents are excluded from diluted net loss per share as they have an anti-dilutive impact.
For the three and nine months ended June 30, 2026, potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows: of stock equivalent warrants; and of stock equivalent employee stock options.
The Company’s discontinued operations relate entirely to SRx Health Solutions, Inc., which was disposed of during the year ended September 30, 2025. Net loss per share from discontinued operations is presented separately in accordance with ASC 205-20 and ASC 260. Basic and diluted net loss per share from discontinued operations are calculated using the same weighted average number of shares as used for continuing operations.
On June 24, 2026, the Company’s Board of Directors approved a 1-for-60 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on July 6, 2026 (see Note 23 – Subsequent events). All share and per-share amounts presented herein, including weighted-average shares outstanding and net loss per share for all periods presented, have been retroactively adjusted to reflect the Reverse Split, in accordance with ASC 260.
| Net loss | Weighted average shares | Loss per share | ||||||||||
| Continuing operations, basic and diluted | $ | ) | $ | ) | ||||||||
| Discontinued operations, basic and diluted | $ | $ | ||||||||||
| Net loss | $ | ( | ) | $ | ) | |||||||
The following table sets forth basic and diluted net loss per share attributable to common stockholders for the nine months ended June 30, 2026 (in thousands, except per share amounts):
| Net loss | Weighted average shares | Loss per share | ||||||||||
| Continuing operations, basic and diluted | $ | ) | $ | ) | ||||||||
| Discontinued operations, basic and diluted | $ | $ | ||||||||||
| Net loss | $ | ( | ) | $ | ) | |||||||
| 36 |
Note 22 – Discontinued operations
On August 11, 2025, the Company’s wholly-owned subsidiary, SRx Health Solutions (Canada) Inc. (“SRx Canada”, “Health Solutions”, or the “Discontinued Operations”), filed for protection under the Companies’ Creditors Arrangement Act (“CCAA”). As a result, the Health Solutions segment has been classified as discontinued operations for all periods presented. The financial statements for the three and nine months ended June 30, 2026 and 2025 reflect only continuing operations, and results of the discontinued Health Solutions segment are presented separately in this footnote.
Results of Operations of Discontinued Operations
The results of operations for the Health Solutions segment included in discontinued operations are as follows (in thousands):
| Three months ended June 30, | Nine months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | $ | $ | $ | ||||||||||||
| Cost of sales | ||||||||||||||||
| Income tax expense (benefit) | ( | ) | ( | ) | ||||||||||||
| Net loss from discontinued operations | ( | ) | ( | ) | ||||||||||||
Cash Flows of Discontinued Operations
The cash flows attributable to the Health Solutions segment are summarized as follows (in thousands):
| Nine months ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows (used in) provided by: | ||||||||
| Operating activities | $ | $ | ( | ) | ||||
| Investing activities | ||||||||
| Financing activities | ||||||||
| Net decrease in cash and cash equivalents | $ | $ | ||||||
Notes and Additional Information
All prior period results for Health Solutions, including the year ended September 30, 2025, are presented within discontinued operations.
All historical acquisitions associated with the Health Solutions segment relate solely to the discontinued business and were fully deconsolidated in connection with the CCAA process; accordingly, no ASC 805 business combination disclosures are included within the Company’s continuing operations.
The financial impact of Health Solutions’ filing under CCAA is reflected in the measurement of net assets and any associated impairment or restructuring charges, if applicable. Refer to Note 12 – Commitments and contingencies for additional details related to obligations of the discontinued operations.
The Company was subject to certain financial covenants under its senior secured term facilities with Canadian Western Bank (“CWB”) related to SRx Canada. As of the date of CCAA filing and subsequent disposal of the business, the Company was not in compliance with these covenants. The debt associated with these facilities has been deconsolidated from the Company’s financial statements. The underlying obligations, however, will not be legally settled or extinguished until completion of the CCAA process.
| 37 |
Note 23 – Subsequent events
The Company has evaluated subsequent events and transactions that occurred after the condensed consolidated statement of financial position date up to the date that the financial statements were issued for potential recognition or disclosure. Other than the following, the Company did not identify any additional subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.
Reverse Stock Split
On
June 24, 2026, the Company’s Board of Directors approved a
All share and per-share amounts presented in these condensed consolidated financial statements, including common shares issued and outstanding, weighted-average shares outstanding, and net loss per share, have been retroactively adjusted to reflect the Reverse Split for all periods presented, in accordance with ASC 260, Earnings Per Share. Because the Reverse Split was approved but not yet legally effective as of June 30, 2026, no recognition of the associated reclassification within Common Stock and Additional Paid-in Capital has been reflected in the Company’s condensed consolidated balance sheet or statement of stockholders’ equity as of that date; this reclassification will be recorded in the period in which the Reverse Split became legally effective.
SRX Global Regains Full Compliance with NYSE American Listing Standards
On July 16, 2026, the Company announced it had received a written notification from NYSE Regulation confirming that the Company is back in compliance with all NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide, including the Section 1003(f)(v) low selling price deficiency addressed by the Reverse Split described above.
In a letter dated July 15, 2026, NYSE Regulation informed the Company that it had resolved the continued listing deficiency with respect to Section 1003(a)(i) and (ii) of the Company Guide, which had been referenced in the Exchange’s letter dated October 14, 2025 and disclosed in the Company’s Form 8-K filed with the SEC on October 17, 2025. As a result, the Company’s compliance indicator (“.BC”) will no longer be disseminated, and SRX Global will be removed from the list of NYSE American noncompliant issuers on the Exchange’s website.
Cash Dividend
On
July 8, 2026, the Company’s Board of Directors approved a one-time cash dividend of $ per share (approximately $
Share Repurchase Program
On
July 7, 2026, the Company’s Board of Directors authorized a share repurchase plan (the “Repurchase Plan”) under which
the Company may repurchase up to million shares of its common stock or up to % of its shares outstanding. The Company has allocated
up to $
Material Definitive Agreement
As
previously disclosed, on March 16, 2026, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”)
with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to shares of the Company’s
Series B convertible preferred stock, par value $ per share (the “Series B Preferred Stock”) and accompanying warrants
(“Warrants”) to purchase shares of the Company’s common stock, par value $ per share (the “Common Stock”)
may be purchased for an aggregate purchase price of up to $
| 38 |
On
July 17, 2026, the Company and the Required Holders, as defined in the Securities Purchase Agreement, entered into a Limited Waiver and
Consent Agreement (the “Waiver”), pursuant to which the Required Holders consented to, and waived certain rights in connection
with, the Company’s (i) declaring and paying, on August 3, 2026, a one-time cash dividend of $ per share on Common Stock outstanding
to stockholders of record at the close of business on July 22, 2026; and (ii) entering into a stock repurchase plan under which the Company
may repurchase up to the lesser of (x) million shares of Common Stock, or (y) 50% of the issued and outstanding Common Stock at
any given time, for an aggregate purchase price not to exceed $
Private Placement
On
July 27, 2026, at an Additional Closing pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors
purchased, in a private placement: shares of the Series B Preferred Stock and Warrants to purchase
May 2026 Convertible Note Receivable
On
July 14, 2026 and August 11, 2026, the Company and the Borrower further amended and restated the May 2026 Note Receivable, pursuant to
which the Company advanced an additional approximately $
Equity Securities Investment
On July 1, 2026, the Company acquired pre-funded warrants to purchase approximately million ordinary shares of a publicly traded company from a third party in exchange for a term note issued by the Company. On the same date, the Company exercised a portion of the pre-funded warrants on a cashless basis and received approximately million ordinary shares of the issuer.
Restricted Stock Award
On July 7, 2026, pursuant to a previously disclosed services agreement, the Company granted restricted shares of the Company’s common stock. The restricted shares are subject to forfeiture during a six-month service period, and the related stock-based compensation expense will be recognized over the applicable service period.
August 2026 Secured Loan
On
August 3, 2026, the Company entered into a credit agreement pursuant to which the Company provided an $
The loan matures upon the earliest of certain specified events, including the consummation of a business combination by the issuer of the pledged equity securities, the winding up of such issuer, or the contractual term date, subject to certain extension rights. Upon consummation of a business combination, the borrower is also required to transfer certain equity securities to the Company.
Equity Line of Credit
Subsequent
to June 30, 2026, the Company issued an aggregate shares of common stock pursuant to its previously disclosed equity line of credit,
for aggregate proceeds of approximately $
| 39 |
| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. |
The following discussion includes forward-looking statements about our business, financial condition and results of operations, including discussions about management’s expectations for our business. The financial condition, results of operations and cash flows discussed in this Management’s Discussion and Analysis of Financial Condition and Results of Operations are those of SRx Health Solutions Inc. and its consolidated subsidiaries, collectively, the “Company,” “SRx,” “we,” “our,” or “us.” These statements represent projections, beliefs and expectations based on current circumstances and conditions and in light of recent events and trends, and you should not construe these statements either as assurances of performance or as promises of a given course of action. Instead, various known and unknown factors are likely to cause our actual performance and management’s actions to vary, and the results of these variances may be both material and adverse. A description of material factors known to us that may cause our results to vary or may cause management to deviate from its current plans and expectations, is set forth under “Risk Factors.” See “Cautionary Note Regarding Forward-Looking Statements.” The following discussion should also be read in conjunction with our audited consolidated financial statements including the notes thereto appearing elsewhere in this filing. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. We undertake no obligation to publicly release the results of any revision to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Overview and Outlook
Following the recent restructuring and the filing for bankruptcy protection by SRx Canada, the Company has undergone a significant transition. As part of this process, the majority of SRx’s former specialty pharmacy, clinical services, and distribution operations have been discontinued or wound down. The business now continues through the Consumer Products segment, which represents the remaining operating platform after the restructuring.
The Consumer Products segment provides a broad portfolio of premium and super-premium pet food and wellness products formulated with high-quality, science-based nutrition under the Halo brand. Unlike the capital-intensive, infrastructure-heavy specialty healthcare model previously operated under the SRx Network, the continuing business has a more streamlined operating footprint, reduced overhead, and a more focused commercial strategy. This shift fundamentally changes the Company’s business profile, risk exposures, and future operating priorities.
The termination of the former specialty healthcare operations has also resulted in a simplified organizational structure. The Company no longer operates specialty pharmacies, clinics, PSP programs, or pharmaceutical distribution facilities, and is no longer positioned as a national specialty healthcare platform. Instead, management is focused on stabilizing the remaining operations, preserving core customer relationships, and ensuring continuity of service while the Company transitions to a more sustainable operating model.
Looking ahead, the Company’s outlook reflects the early stages of this reset. Near-term priorities include strengthening the financial position of the continuing operations, optimizing cost structure, and re-establishing a focused growth path that aligns with the capabilities and market positioning of the Consumer Products business. While the restructuring has materially reduced the scale and scope of the Company compared to prior periods, management believes that the streamlined business provides a clearer path to operational stability and disciplined execution.
The Company will continue evaluating strategic alternatives to support the long-term viability of the business, including potential partnerships, product expansion opportunities, and targeted investments that align with the strengths of the continuing operations.
Recent Corporate Developments
Merger and CCAA Proceedings
On September 3, 2024, Better Choice Company, Inc. (“Predecessor”), SRx Canada, 1000994476 Ontario Inc. (“AcquireCo”), a corporation existing under the laws of the Province of Ontario and an indirect wholly-owned subsidiary of Predecessor, and 1000994085 Ontario Inc., a corporation existing under the laws of the Province of Ontario and a direct wholly-owned subsidiary of Predecessor (“CallCo”) entered into an Arrangement Agreement (the “Arrangement Agreement”), and the transactions contemplated thereby (the “Merger”) were completed on April 24, 2025 (which is referred to herein as the “Closing Date”). Pursuant to the Arrangement Agreement, on the Closing Date, AcquireCo merged with and into SRx Canada, with SRx Canada remaining as the surviving entity. Predecessor acquired the business of SRx Canada pursuant to the Merger.
In connection with the Merger, on April 24, 2025, Predecessor changed its corporate name from “Better Choice Company Inc.” to “SRx Health Solutions, Inc.” by the filing of a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware, and SRx Canada changed its name from “SRx Health Solutions Inc.” to “SRx Health Solutions (Canada) Inc.” by making the appropriate filing in the Province of Ontario.
| 40 |
On the Closing Date, Predecessor issued to certain holders of the common stock of SRx Canada 8,898,069 shares of the Company’s Common Stock, and AcquireCo issued to certain holders of the common stock of SRx Canada 19,701,935 shares in the capital stock of AcquireCo which shares are exchangeable into shares of the Company’s Common Stock (the “Exchangeable Shares”) on a one-for-one basis.
On August 12, 2025, the Company announced that SRx Canada had obtained an Initial Order (the “Initial Order”) in Canada under the federal Companies’ Creditors Arrangement Act (the “CCAA” and SRx Canada’s proceedings thereunder, the “CCAA Proceedings”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”). In connection with the Initial Order, the Court granted, among other relief, a stay of proceedings in favor of SRx Canada, the appointment of Grant Thornton Limited as the monitor of SRx Canada (in such capacity, the “Monitor”), debtor-in-possession financing (“DIP Financing”), and a sale process (“Sale Process”).
SRx Canada has secured debtor-in-possession (DIP) Financing (which includes insider participation). The DIP Financing consists of a credit facility of up to a maximum of $1,750,000 which is expected to be used to finance SRx Canada’s working capital needs, including for continued operations and to implement the restructuring contemplated by the CCAA Proceedings. The CCAA Proceedings and DIP Financing will provide SRx Canada with the time and stability required to complete the Sale Process and identify transaction(s) which may include the sale of all or substantially all of the business or assets of SRx Canada. The Company intends to carry on the critical business of SRx Canada throughout the pendency of the CCAA Proceedings.
Neither the Company nor the Company’s United States subsidiary, Halo, Purely For Pets, Inc., a Delaware corporation, has made any filing under any bankruptcy code or statutory reorganization scheme either in the United States or in Canada.
On August 14, 2025, the Company entered into a Settlement, Share Forfeiture and Mutual Release Agreement (the “Settlement Agreement”) with certain of the founders and officers of SRx Canada (the “Forfeiting Stockholders”), pursuant to which the Forfeiting Stockholders forfeited for cancellation approximately 313,988 Exchangeable Shares (the “Forfeited Shares”). In consideration of the Forfeited Shares, the Company agreed to release the Forfeiting Stockholders from certain claims by the Company.
July PIPE Financing
On July 7, 2025, the Company entered into the Securities Purchase Agreement (the “July PIPE SPA”) by and among the Company and the July PIPE Investors, including the lead investor (the “Lead Investor”), pursuant to which the Company issued and sold to the Investors (i) a new series of senior secured convertible notes (the “July Notes”) with an aggregate original principal amount of $7,650,000, subject to an original issue discount as provided in the July Notes, and (ii) warrants (the “July Warrants”) to acquire 355,635 shares of the Company’s common stock (the “Common Stock”) (such transaction, the “July PIPE Financing”).
The July Notes bear interest at a rate of 8% per annum. The July Notes mature on July 8, 2027, provided that the maturity date may be extended by a noteholder if the Company is in default under the July Notes, and in certain other limited circumstances as described in the July Notes. The July Notes are convertible into shares of the Common Stock at a conversion price of $37.64 per share, subject to customary adjustments. The July Warrants are exercisable for a period of three (3) years beginning six (6) months from the date of issuance at an exercise price of $37.64 per share, also subject to adjustment.
Additionally, on July 8, 2025, pursuant to and in connection with the July PIPE SPA, the Company entered into a Security and Pledge Agreement (the “Security Agreement”) by and between the Company and the Lead Investor, in its capacity as collateral agent, pursuant to which the Company granted to the Lead Investor, for the ratable benefit of the Lead Investor and the other July PIPE Investors, a valid, perfected and enforceable security interest in certain assets of the Company and its subsidiaries, which assets include substantially all of the assets of the Company’s U.S. business, and pledged as collateral the equity held by the Company in certain of the Company’s subsidiaries.
Additionally, on July 8, 2025, pursuant to and in connection with the July PIPE SPA, the Company and the July PIPE Investors entered into a Registration Rights Agreement (the “July PIPE RRA”), pursuant to which the Company agreed to file a registration statement with the United States Securities and Exchange Commission (“SEC”) covering the resale of Common Shares that are issuable upon the conversion of the July Notes or the exercise of the July Warrants.
Additionally, on December 23, 2025, pursuant to and in connection with the July PIPE SPA, the Company and the July PIPE Investors utilized a portion of available liquidity to fully repay the outstanding principal and accrued interest on the July PIPE Notes, thereby extinguishing all related debt obligations. For more information, see SRx Health Solutions, Inc.’s Form S-1/A filed on December 23, 2025.
| 41 |
October PIPE Financing
On October 27, 2025, the Company entered into a Securities Purchase Agreement (the “October PIPE SPA”) with certain accredited investors named therein (the “October PIPE Investors”). Certain October PIPE Investors are July PIPE Investors. Pursuant to the October PIPE SPA, up to 635 shares of the Company’s Series A convertible preferred stock, par value $0.001 per share (the “Series A Preferred Stock”) and accompanying warrants (“October Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) may be purchased for an aggregate purchase price of up to $30.46 million in one or more closings (such transaction, the “October PIPE Financing”).
On October 27, 2025, in connection with the October PIPE Financing, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designations establishing the rights, preferences, and privileges of the newly authorized Series A Preferred Stock.
On October 31, 2025, pursuant to the October PIPE SPA, the Company issued and sold, and the October PIPE Investors purchased, in a private placement: 318 shares of the Series A Preferred Stock and 908,797 October Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $14.0 million, paid in cash or through the cancellation of such October PIPE Investor’s July Note and July in lieu of cash. The Company waived receipt of the cash portion of the purchase price until November 3, 2025. Pursuant to the October PIPE SPA, the July PIPE Investors waived the requirement under the July PIPE SPA that the Company register for resale 250% of the shares of Common Stock issuable upon the conversion or exercise of the July Notes or July Warrants.
In conjunction with the October PIPE SPA, on October 31, 2025 the Company entered a registration rights agreement with the investors (the “October PIPE RRA”), pursuant to which the Company will be required to file a registration statement with the Securities and Exchange Commission (the “SEC”), to register for resale the Common Stock issuable upon (x) the conversion of the Series A Preferred Stock and (y) the exercise of the October Warrants.
ELOC Transaction
Concurrently with the issuance of the Notes and Warrants described above under “July PIPE Financing,” on July 7, 2025, the Company and the Selling Stockholder entered into a common share purchase agreement (as amended, the “ELOC Purchase Agreement”), which provides that subject to the terms and conditions set forth therein, the Company may sell to the Selling Stockholder up to the lesser of (i) $50 million of the Company’s common shares, no par value (the “Common Share”) and (ii) the Exchange Cap (as defined below) (subject to certain exceptions provided in the ELOC Purchase Agreement) (the “Total Commitment”), from time to time during the term of the ELOC Purchase Agreement. On October 28, 2025, the Company and the Selling Stockholder executed an amendment to the ELOC Purchase Agreement increasing the Total Commitment from $50 million to $1.0 billion (the “ELOC Amendment”).
Additionally, on July 7, 2025, the Company and the Selling Stockholder entered into a registration rights agreement (the “ELOC RRA”), pursuant to which the Company agreed to file this registration statement with the United States Securities and Exchange Commission (“SEC”) covering the resale of Common Shares that are issued to the Selling Stockholder under the ELOC Purchase Agreement (the “Registration Statement”).
On October 28, 2025, the Selling Stockholder executed a waiver with respect to the ELOC Purchase Agreement and ELOC RRA which waivers allows the Company to register just $27.55 million of Common Stock under the Initial Registration Statement (as defined in the ELOC RRA), rather than $1 billion of Common Stock, due to the constraints of the Company’s currently authorized capital. In the event that the Company’s authorized capital increases, the Company intends to amend this Registration Statement to register an additional $972.45 million of Common Stock, subject to the ELOC Purchase Agreement and ELOC RRA.
Under the terms and subject to the satisfaction of the conditions set forth in the ELOC Purchase Agreement, the Company has the right, but not the obligation, to sell to the Selling Stockholder, and the Selling Stockholder is obligated to purchase, up to the Total Commitment. Such sales of Common Shares by the Company, if any, will be subject to certain limitations as set forth in the ELOC Purchase Agreement, and may occur from time to time, at the Company’s sole discretion, over the period commencing on the date that all of the conditions to the Company’s right to commence such sales are satisfied, including that the registration statement referred to above is declared effective by the SEC and a final form of the prospectus included therein is filed with the SEC (the “Commencement Date”) and ending upon the expiration of this Registration Statement pursuant to Rule 4125(a)(5) of the Securities Act of 1933, as amended, or otherwise upon the termination of the ELOC Purchase Agreement as provided therein. The Selling Stockholder has no right to require the Company to sell any Common Shares to the Selling Stockholder, but the Selling Stockholder is obligated to make purchases as the Company directs, subject to satisfaction of the conditions set forth in the ELOC Purchase Agreement.
As consideration for the Lead Investor entering into the ELOC Purchase Agreement, concurrently with the execution of the ELOC Amendment, the Company issued to the Lead Investor a convertible promissory note in the original principal amount of $20.0 million (the “ELOC Commitment Note”), which is convertible into up to 1,200,811 shares of Common Stock (collectively, the “ELOC Commitment Shares”), assuming a price of $19.26 per share, which was the closing price of our shares of Common Stock on the NYSE American on October 22, 2025. The ELOC Commitment Note was issued by the Company to the Lead Investor in lieu of the Commitment Shares, as defined in the original ELOC Purchase Agreement. The Company also agreed to pay the Lead Investor up to $35,000 for its reasonable expenses under the ELOC Purchase Agreement.
| 42 |
EMJX Asset Acquisition
On June 16, 2026, the Company completed a transaction with EMJ Crypto Technologies Inc., a corporation organized under the laws of Ontario, Canada (“EMJC”), pursuant to a Share Exchange and Asset Transfer Agreement, dated December 16, 2025, and amended on March 11, 2026 and June 17, 2026 (as amended, the “Transfer Agreement”), by and among the Company, EMJC, CCC Crypto Corp., a Delaware corporation (“CCC Crypto”), 1001440571 Ontario Inc., a corporation organized under the laws of Ontario, Canada and an indirect wholly-owned subsidiary of the Company (“ExchangeCo”), and the other parties thereto (the “Transaction”).
At the closing of the Transaction (the “Closing”), the Company acquired 100% of the issued and outstanding equity interests of each of EMJC and CCC Crypto, and a 100% direct and indirect ownership interest in the IP Asset, as defined in the Transfer Agreement.
As consideration, the Company issued to EMJC and certain other parties to the Transaction an aggregate of (i) 4,718,937 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), (ii) 1,954,470 exchangeable shares of ExchangeCo (the “Exchangeable Shares”) which are exchangeable for shares of Common Stock on a one-for-one basis, and (iii) warrants (the “Pre-Funded Warrants”) to purchase 492,984 shares of Common Stock.
The shares of Common Stock issued at the Closing, and the shares of Common Stock issuable upon the exchange or exercise of the Exchangeable Shares and Pre-Funded Warrants issued at the Closing, have been registered under the Securities Act of 1933, as amended (the “Securities Act”) in a Registration Statement on Form S-4 declared effective by the SEC on May 7, 2026.
The Transaction was accounted for as an asset acquisition in accordance with ASC 805-50. The fair value of the equity consideration transferred in the Transaction was $79.7 million. Additionally, the Company incurred direct acquisition-related transaction costs of $0.3 million, consisting primarily of legal, accounting and other professional fees, incurred in connection with the Closing and thus were capitalized as part of the cost of the assets acquired. Accordingly, the total purchase price for accounting purposes was $80.0 million.
Reverse Stock Split
As previously disclosed, the Company was notified on October 14, 2025 that it was not in compliance with certain continued listing standards. Subsequent to December 31, 2025, the Company received notice from NYSE American that it had accepted the Company’s plan to regain compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide on January 6, 2026. As a result, the Company’s common stock will continue trading on the NYSE American during an extension period through July 14, 2026, during which the Company must provide quarterly progress updates. The Company intends to regain compliance during the extension period.
On June 23, 2026, the Company was informed by the NYSE American LLC (the “NYSE American”) that it was not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide, which relates to low selling price per share for a substantial period of time. The Company’s common stock closed below $0.10 on June 23, 2026, and NYSE American halted trading of the Company’s common stock, with the halt to continue until the Company effectuated a reverse stock split.
In response, on June 24, 2026, the Company announced its plan to proceed with a 1-for-60 reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share, as a measure the Company believes is necessary and in the best interests of the Company and its stockholders to regain compliance with NYSE American’s continued listing standards. The reverse stock split became effective July 6, 2026. See Note 23 – Subsequent events, for discussion of the reverse stock split.
| 43 |
On June 24, 2026, the Company’s Board of Directors approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 (the “Reverse Split”). The Reverse Split became effective, and trading on a post-split basis began, at the market open on July 6, 2026. There was no change to the par value of the Company’s common stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder’s ownership percentage of the Company’s shares with the exception of those holders of fractional shares. No fractional shares were issued in connection with the Reverse Split; any shareholder who would otherwise have been entitled to a fractional share received one whole share in lieu thereof.
On July 16, 2026, the Company announced it had received a written notification from NYSE Regulation confirming that the Company is back in compliance with all NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide, including the Section 1003(f)(v) low selling price deficiency addressed by the Reverse Split described above.
In a letter dated July 15, 2026, NYSE Regulation informed the Company that it had resolved the continued listing deficiency with respect to Section 1003(a)(i) and (ii) of the Company Guide, which had been referenced in the Exchange’s letter dated October 14, 2025 and disclosed in the Company’s Form 8-K filed with the SEC on October 17, 2025. As a result, the Company’s compliance indicator (“.BC”) will no longer be disseminated, and SRX Global will be removed from the list of NYSE American noncompliant issuers on the Exchange’s website.
Redemption of Preferred Stock
On February 9, 2026, the Company exercised its right under Section 9 of the Certificate of Designations filed on October 27, 2025 to redeem all outstanding shares of its preferred stock by February 12, 2026. As of the date of the redemption notice, there were 17,418 shares of preferred stock outstanding. The redemption price is payable in cash at 125% of the $1,000 conversion amount per share, or $1,250 per share, for an aggregate redemption price of approximately $21.8 million.
Other Matters
The Company appointed two new directors to its Board. Joshua Epstein joined the Board effective October 1, 2025, and Sammy Dorf, Esq. was appointed effective November 10, 2025.
On October 8, 2025, the Company’s stockholders, acting by written consent, approved several corporate actions. These actions included authorizing certain issuances of common stock and convertible securities, approving a future private equity offering of securities, amending the Certificate of Incorporation to increase the number of authorized shares, amending the Bylaws to reduce quorum requirements for stockholder meetings, and authorizing an additional reverse stock split of the Company’s common stock at a ratio to be determined by the Board.
On October 31, 2025, the Company accepted the voluntary resignations of directors Lionel F. Conacher and David Allen White. Following these resignations, Michael Young, Simon Conway, and Joshua A. Epstein were appointed to serve on each of the Audit, Compensation, and Nominating & Governance Committees, with each member designated as chairman of one of the committees.
On November 19, 2025, the Company filed a Certificate of Amendment with the Secretary of State of the State of Delaware which increased the number of shares of Common Stock that the Company is authorized to issue from 200,000,000 shares to 5,000,000,000 shares.
Results of Operations for the three months ended June 30, 2026 and 2025
The following table sets forth our condensed consolidated results for the periods presented (in thousands):
Three Months Ended June 30, | Change | Nine Months Ended June 30, | Change | |||||||||||||||||||||||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |||||||||||||||||||||||||
| Net sales | $ | 3,392 | $ | 2,673 | $ | 719 | 27 | % | $ | 9,638 | $ | 2,673 | $ | 6,965 | 261 | % | ||||||||||||||||
| Cost of goods sold | 2,488 | 2,642 | (154 | ) | (6 | )% | 6,405 | 2,642 | 3,763 | 142 | % | |||||||||||||||||||||
| Gross profit | 904 | 31 | 873 | 2816 | % | 3,233 | 31 | 3,202 | 10329 | % | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||
| Selling, general and administrative | 4,105 | 8,637 | (4,532 | ) | (52 | )% | 12,042 | 8,637 | 3,405 | 39 | % | |||||||||||||||||||||
| Loss from continuing operations | (3,201 | ) | (8,606 | ) | 5,405 | 63 | % | (8,809 | ) | (8,606 | ) | (203 | ) | 2 | % | |||||||||||||||||
| Other expense (income): | ||||||||||||||||||||||||||||||||
| Interest expense, net | 569 | (30 | ) | 599 | 1997 | % | 3,637 | (30 | ) | 3,667 | (12223 | )% | ||||||||||||||||||||
| Loss/(Gain) on extinguishment of debt | (469 | ) | — | (469 | ) | * | 2,588 | — | 2,588 | * | ||||||||||||||||||||||
| Change in fair value of digital assets | 1,410 | — | 1,410 | * | 4,768 | — | 4,768 | * | ||||||||||||||||||||||||
| Change in fair value of equity securities | (12 | ) | — | (12 | ) | * | 481 | — | 481 | * | ||||||||||||||||||||||
| Change in fair value of derivative liabilities | (578 | ) | — | (578 | ) | * | (1,170 | ) | — | (1,170 | ) | * | ||||||||||||||||||||
| Bargain purchase gain | — | (1,693 | ) | 1,693 | 100 | % | — | (1,693 | ) | 1,693 | (100 | )% | ||||||||||||||||||||
| Other income, net | 19 | (32 | ) | 51 | 100 | % | 16 | (32 | ) | 48 | (150 | )% | ||||||||||||||||||||
| Total other expense, net | 939 | (1,755 | ) | 2,694 | 154 | % | 10,320 | (1,755 | ) | 12,075 | (688 | )% | ||||||||||||||||||||
| Net loss before income taxes | (4,140 | ) | (6,851 | ) | 2,711 | 40 | % | (19,129 | ) | (6,851 | ) | (12,278 | ) | 179 | % | |||||||||||||||||
| Income tax expense | — | — | — | —% | 6 | — | 6 | * | ||||||||||||||||||||||||
| Net loss from continuing operations | (4,140 | ) | (6,851 | ) | 2,711 | 40 | % | (19,135 | ) | (6,851 | ) | (12,284 | ) | 179 | % | |||||||||||||||||
| Loss from discontinued operations | — | (8,282 | ) | 8,282 | (100 | )% | — | (22,894 | ) | 22,894 | (100 | )% | ||||||||||||||||||||
| Net loss | $ | (4,140 | ) | $ | (15,133 | ) | $ | 10,993 | 73 | % | $ | (19,135 | ) | $ | (29,745 | ) | $ | 10,610 | (36 | )% | ||||||||||||
* Percentage change is not meaningful due to a prior year balance of zero.
| 44 |
Net sales
We generate revenue primarily through the sale of premium and super-premium pet food and wellness products under the Halo brand. Revenue is recognized when control transfers to the customer, generally at the point of sale through our digital, international, or brick-and-mortar channels. Most transactions involve a single performance obligation. Reported net sales are reduced by trade promotions, discounts, and other customer incentives, which are estimated and recorded as reductions to gross revenue. We also maintain a reserve for expected product returns based on historical experience. Following the restructuring of SRx Canada and the CCAA proceedings, the Company no longer derives material revenue from specialty pharmacy, clinical services, diagnostics, or pharmaceutical distribution, and its current operations are focused exclusively on the pet health and wellness business.
Information about our revenue channels is as follows (in thousands):
| Three months ended June 30, | Nine months ended June 30, | |||||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||||||
| Digital (1) | $ | 2,267 | 67 | % | $ | 1,735 | 65 | % | $ | 7,722 | 80 | % | $ | 1,735 | 65 | % | ||||||||||||||||
| International (2) | 1,081 | 32 | % | 613 | 23 | % | 1,433 | 15 | % | 613 | 23 | % | ||||||||||||||||||||
| Brick & Mortar (3) | 44 | 1 | % | 325 | 12 | % | 483 | 5 | % | 325 | 12 | % | ||||||||||||||||||||
| Net Sales (4) | $ | 3,392 | 100 | % | $ | 2,673 | 100 | % | $ | 9,638 | 100 | % | $ | 2,673 | 100 | % | ||||||||||||||||
| (1) | The Company’s Digital channel includes two wholesale customers that amounted to greater than 10% of the Company’s total net sales for the three and nine months ended June 30, 2026 and June 30, 2025. Net sales represented $2.2 million and $7.5 million of net sales for the three and nine months ended June 30, 2026. Net sales represented $1.7 million of net sales for both the three and nine months ended June 30, 2025. |
| (2) | One of the Company’s International customers amounted to greater than 10% of the Company’s total net sales, representing $0.8 million and $1.1 million of net sales for the three and nine months ended June 30, 2026, respectively. For the three and nine months ended June 30, 2025, one of the Company’s International customers amounted to greater than 10% of the Company’s total net sales, representing $0.4 million in each period. |
| (3) | None of the Company’s Brick & Mortar customers represented greater than 10% of net sales for either the three and nine months ended June 30, 2026 and June 30, 2025. |
| (4) | Prior period amounts have been presented only for Better Choice Company, Inc., as the prior year operations of SRX Canada have been deconsolidated and are presented as discontinued operations. Accordingly, the results for the three and nine months ended June 30, 2026 and June 30, 2025, reflect only the continuing operations of BTTR and Halo and are not comparable to prior periods. |
Net sales for three and nine months ended June 30, 2026 were $3.4 million and $9.6 million, respectively, reflecting revenue generated from the Company’s continuing operations in the Halo pet health and wellness business. Net sales were driven by the sale of premium and super-premium pet food products across digital, brick-and-mortar, and international channels, reflecting the Company’s focus on product innovation, brand awareness, and meeting consumer demand in multiple trade channels.
Prior-year results reflect only the results for the Halo business within the Better Choice Company, Inc. The operations of SRx Canada, the Company’s former specialty healthcare business, were deconsolidated during the prior year and are presented as discontinued operations. Accordingly, prior year amounts for SRx Canada are not presented. As a result, and given the Company’s focus on the Consumer Products business, net sales for three months ended June 30, 2026 are not directly comparable to the corresponding 2025 periods.
Gross profit
Cost of goods sold consists primarily of the cost of products obtained from co-manufacturers, packaging materials, freight costs for shipping inventory to the warehouse, and third-party warehouse and order fulfillment expenses. Inventories are periodically reviewed to identify damaged, slow-moving, or aged inventory. Based on this assessment, inventory is recorded at the lower of cost or net realizable value, with any reduction in value expensed as cost of goods sold.
Our products are manufactured to our specifications by co-manufacturers using raw materials that meet our formulation requirements. Co-manufacturers also handle product testing and packaging, with packaging designed by the Company and shipped directly to the manufacturer.
Gross profit is affected by a variety of factors, including product sales mix, volumes sold, discounts offered to customers, the cost of manufactured products, and freight costs from the manufacturer to the warehouse. For the three months ended June 30, 2026, gross profit was 0.9 million, with a gross margin of 27%. For the nine months ended June 30, 2026, gross profit was $3.2 million, with a gross margin of 34%.
We continue to work with co-manufacturing and freight partners to realize future cost savings and improved gross margins. However, gross margins may continue to fluctuate due to inflationary pressures on transportation and raw material costs. We will continue to refine and optimize our pricing strategy to align with market conditions and manage cost pressures.
Operating expenses
Our Selling, general and administrative (“SG&A”) expenses consist of the following:
| ● | Sales and marketing costs for the three and nine months ended June 30, 2026 primarily reflect agency fees and direct marketing associated with supporting the Halo brand portfolio. These expenses include fees paid to third-party marketing and advertising agencies as well as service charges related to external sales and promotional activities. Prior-year results reflect only the results of the Halo business within Better Choice Company, Inc. Following the reverse takeover, the operations of SRx Canada were deconsolidated, and its prior-year amounts are therefore not presented; accordingly, prior period amounts are not directly comparable. Sales and marketing spend in the three and nine months ended June 30, 2026 reflects the Company’s strategic focus on strengthening brand awareness, improving conversion across key e-commerce platforms, and optimizing channel-specific promotional activity, while remaining disciplined in its approach to paid media investment. | |
| ● | Employee compensation and benefits for the three and nine months ended June 30, 2026 reflect personnel costs associated with the Company’s continuing operations in the Halo pet health and wellness business. These expenses include salaries, wages, benefits, and stock-based compensation for employees supporting operations, marketing, supply chain, and corporate functions. Current-year expense levels represent the ongoing cost structure of the standalone Halo business and are not directly comparable to prior periods. |
| 45 |
| ● | Share-based compensation includes expenses related to equity awards granted to employees and non-employee directors. For the three and nine months ended June 30, 2026, share-based compensation reflects the ongoing equity incentive programs of the continuing Halo business, including expense recognition for outstanding awards, new grants issued during the period, and common stock issued for board service. Share-based compensation in the three and nine months ended June 30, 2026 also reflects the vesting patterns of historical Better Choice equity awards. Because the Company became the reporting entity following the reverse takeover and the SRx Canada operations were subsequently discontinued, prior-year comparative amounts are not directly comparable. Current-year expense therefore represents the continuing cost structure of the standalone Halo business. | |
| ● | Freight costs for the three and nine months ended June 30, 2026 primarily relate to the shipping and logistics associated with fulfilling customer orders across the Company’s retail and e-commerce sales channels. Freight activity in the current period is primarily driven by shipments to distribution partners, online retailers, and brick-and-mortar customers rather than individual consumer deliveries. Given the changes in the Company’s operating structure following the reverse takeover and the discontinuation of SRx Canada, prior-year comparisons are not directly comparable. Current freight costs therefore reflect the ongoing logistics profile of the standalone Halo business. | |
| ● | Non-cash charges for the three and nine months ended June 30, 2026 primarily consisted of depreciation, amortization, and bad debt expense. Given the impact of the reverse takeover and the discontinuation of the SRx Canada operations, prior-year comparative amounts are not directly comparable. Current-year non-cash activity reflects the operating profile of the standalone Halo business. | |
| ● | Other general and administrative costs for the three and nine months ended June 30, 2026 primarily reflect expenses incurred for professional services, insurance, and corporate compliance activities. The most significant components for the three months ended June 30, 2026 included professional fees — including legal, financial advisory, and other consulting services — totaling approximately $1.2 million, incremental expenses of approximately $0.6 million, and insurance expense of approximately $0.2 million. The most significant components for the nine months ended June 30, 2026 included professional fees — including legal, financial advisory, and other consulting services — totaling approximately $4.3 million, incremental expenses of approximately $1.4 million, insurance expense of approximately $0.6 million, and SEC filing fees of approximately $0.4 million. These costs also include routine corporate expenses such as director fees, state feed registration fees, and information technology support. Given the reverse takeover and the discontinuation of the SRx Canada operations, prior-year comparative amounts are not directly comparable. Current-year costs reflect the operating and capital markets activities of the standalone Halo business. |
Interest expense, net
Interest expense for the three and nine months ended June 30, 2026 primarily reflects interest associated with the ELOC Commitment Note issued in October 2025. The period also includes interest incurred on the July 2025 notes, which were fully written off in October 2025, including all outstanding principal and accrued interest. As a result, no further interest was recognized on those instruments for the remainder of the period.
Income taxes
Our income tax expense now reflects only the tax position of the continuing U.S. operations following the discontinuation and deconsolidation of the SRx Canada business as a result of the CCAA proceedings. Accordingly, the Company’s tax provision is based on estimated U.S. federal and state income taxes, adjusted for nondeductible items and the impact of the valuation allowance.
For the three months ended June 30, 2026, the Company recorded no material income tax expense or benefit, resulting in a near-zero effective tax rate. For the nine months ended June 30, 2026, the Company recorded an income tax benefit of less than $0.01 million, which similarly did not result in a meaningful effect tax rate. The Company recorded no material income tax expense or benefit for the comparative three and nine months ended June 30, 2025. The absence of a significant tax expense or benefit in either period is primarily due to the continued maintenance of a full valuation allowance that fully offsets deferred tax assets arising from current-year losses.
The Company continues to maintain a full valuation allowance against its U.S. deferred tax assets due to uncertainties regarding the timing and likelihood of generating sufficient future taxable income. Deferred tax assets consist primarily of U.S. federal and state net operating loss (“NOL”) carryforwards, which total approximately $24.0 million on a tax-effected basis and begin to expire at various dates unless utilized. The Company will continue to evaluate both positive and negative evidence each reporting period to determine whether a release of the valuation allowance is warranted. A reversal of the valuation allowance in future periods would reduce income tax expense.
The Company had no uncertain tax positions as of June 30, 2026 and 2025. We remain subject to examination in the United States for tax years 2021 through 2026.
| 46 |
Non-GAAP Measures
Adjusted EBITDA
We define Adjusted EBITDA to supplement the financial measures prepared in accordance with GAAP. Adjusted EBITDA adjusts EBITDA to eliminate the impact of certain items that we do not consider indicative of our core operations. Adjusted EBITDA is determined by adding the following items to net loss: interest expense, depreciation and amortization, tax expense, share-based compensation, loss on extinguishment of debt, change in fair value of digital assets, change in fair value of equity securities, change in fair value of derivative liabilities, transaction-related expenses, and other non-recurring expenses.
We present Adjusted EBITDA as a key measure used by our management and board of directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. We believe that the disclosure of Adjusted EBITDA is useful to investors as this non-GAAP measure forms the basis of how our management team reviews and considers our operating results. By disclosing this non-GAAP measure, we believe that we create for investors a greater understanding of and an enhanced level of transparency into the means by which our management team operates our company. We also believe this measure can assist investors in comparing our performance to that of other companies on a consistent basis without regard to certain items that do not directly affect our ongoing operating performance or cash flows.
Adjusted EBITDA does not represent cash flows from operations as defined by GAAP. Adjusted EBITDA has limitations as a financial measure and you should not consider it in isolation, or as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including various cash flow metrics, net loss, gross margin, and our other GAAP results.
The following table presents a reconciliation of net loss, the closest GAAP financial measure, to EBITDA and Adjusted EBITDA for each of the years indicated (in thousands):
| Three Months Ended June 30, | Nine Months Ended June 30, | |||||||||||||||
| 2026 | 2025* | 2026 | 2025* | |||||||||||||
| Net loss | $ | (4,140 | ) | $ | (6,851 | ) | $ | (19,135 | ) | $ | (6,851 | ) | ||||
| Interest expense, net | 569 | (30 | ) | 3,637 | (30 | ) | ||||||||||
| Depreciation and amortization | 15 | 16 | (46 | ) | 16 | |||||||||||
| Income tax expense | — | — | 6 | — | ||||||||||||
| EBITDA | (3,556 | ) | (6,865 | ) | (15,538 | ) | (6,865 | ) | ||||||||
| Non-cash share-based compensation (a) | — | 2,032 | 961 | 2,032 | ||||||||||||
| Loss/(Gain) on extinguishment of debt | (469 | ) | — | 2,588 | — | |||||||||||
| Change in fair value of digital assets | 1,410 | — | 4,768 | — | ||||||||||||
| Change in fair value of equity securities | (12 | ) | — | 481 | — | |||||||||||
| Change in fair value of derivative liabilities | (578 | ) | — | (1,170 | ) | — | ||||||||||
| Bargain purchase gain | — | (1,693 | ) | — | (1,693 | ) | ||||||||||
| Transaction related (b) | 1,451 | 4,017 | 4,218 | 4,017 | ||||||||||||
| Non-recurring and other expenses (c) | 184 | 85 | 463 | 85 | ||||||||||||
| Adjusted EBITDA | $ | (1,570 | ) | $ | (2,424 | ) | $ | (3,229 | ) | $ | (2,424 | ) | ||||
(a) Non-cash expenses related to equity compensation awards for certain directors, officers and employees for services in their capacity as such.
(b) Represents transaction, financing, treasury, litigation, and other non-recurring corporate costs, including legal, audit, valuation, professional, SEC filing, due diligence, transfer agent, and capital markets-related fees associated with the Company’s financing, treasury, and trading activities, which are not considered part of normal recurring operations.
(c) Other single-occurrence expenses, which consist of strategic rebranding, systems implementation and technology transformation, initiatives and other non-recurring costs.
*Prior-year results reflect only the results for the Halo business within the Better Choice Company, Inc. The operations of SRx Canada, the Company’s former specialty healthcare business, were deconsolidated during the fiscal year September 30, 2025 and are presented as discontinued operations. Accordingly, prior year amounts for SRx Canada are not presented.
| 47 |
Liquidity and capital resources
Historically, we have financed our operations primarily through debt and equity financing. On June 30, 2026 and September 30, 2025, we had cash and cash equivalents of $36.7 million and $1.3 million, respectively, and short-term investments of $7.5 million and zero, respectively.
A summary of our cash flows is as follows (in thousands):
| Nine months ended June 30, | ||||||||
| 2026 | 2025* | |||||||
| Cash flows (used in) provided by: | ||||||||
| Operating activities | $ | (10,505 | ) | $ | (1,773 | ) | ||
| Investing activities | (24,188 | ) | (3,400 | ) | ||||
| Financing activities | 70,070 | (390 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | $ | 35,377 | $ | (5,563 | ) | |||
*Following the reverse merger completed during the fiscal year ended September 30, 2025, the Company’s operating structure changed, and SRx Canada was subsequently discontinued. As a result, prior-year comparative figures reflect the historical operations of SRx Canada. These operations have since been deconsolidated and are reported as discontinued operations.
Cash flows from operating activities
Cash used in operating activities was $10.5 million during the nine months ended June 30, 2026 compared to cash used in operating activities of $1.8 million during the nine months ended June 30, 2025. The increase in cash used in operating activities was primarily driven by a $19.1 million net loss and $1.2 million change in fair value of derivative liabilities, offset by a $4.8 million change in fair value of digital assets and $2.6 million loss on settlement of debt.
Cash flows from investing activities
Cash used in investing activities was $24.2 million during the nine months ended June 30, 2026 compared to cash used in investing activities of $3.4 million during the nine months ended June 30, 2025. Cash used in investing activities was primarily related to the purchase of digital assets of $16.5 million and purchase of equity securities of 5.2 million, partially offset by proceeds from sale of digital assets of $9.6 million. The Company also purchased $158.6 million of marketable securities and option positions as part of its active capital allocation and treasury management activities, offset by a $159.2 million of proceeds from sales of marketable securities and option positions. Additionally, the Company invested approximately net $7.5 million in short-term U.S. Treasury securities as part of its broader treasury management strategy and purchased a net $4.9 million of convertible note receivables, as described in Note 7 – Notes receivable.
Cash flows from financing activities
Cash provided by financing activities was $70.1 million during the nine months ended June 30, 2026 compared to cash used in financing activities of $0.4 million during the nine months ended June 30, 2025. The cash provided by financing activities for the nine months ended June 30, 2026 was mainly related to proceeds from the issuance of common stock of $80.3 million and the issuance of convertible preferred stock of $13.4 million, primarily offset by the redemption of Series A convertible preferred stock of $21.8 million.
Contractual Commitments and Obligations
We are contractually obligated to make future cash payments for various items, including debt arrangements and certain purchase obligations. See “Note 10 – Debt” to our interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information about our debt obligations. Our purchase obligations include certain ongoing marketing projects, software subscriptions as well as in-transit or in-production purchase orders with our suppliers, for which amounts vary depending on the purchasing cycle. The majority of our software subscriptions are not under long-term contracts, and we do not have long-term contracts or commitments with any of our suppliers beyond active purchase orders. These purchase obligations were not material as of the date of this Quarterly Report on Form 10-Q.
Off-Balance Sheet Arrangements
On July 7, 2025, the Company entered into a Common Share Purchase Agreement (the “ELOC”) with a lead investor, under which the Company may sell, at its discretion, up to $50.0 million of its common shares, subject to certain conditions and limitations, including the NYSE American 19.99% Exchange Cap unless stockholder approval is obtained or sales otherwise qualify as “at-market” under applicable rules. The investor is obligated to purchase shares when directed by the Company, subject to the terms of the ELOC, and may not beneficially own more than 4.99% of the Company’s outstanding common shares following any purchase.
On October 28, 2025, the Company and the investor agreed to amend the ELOC to increase the total commitment from $50 million to $1 billion. In connection with such amendment, the Company issued to Investor a convertible promissory note in the aggregate principal amount of $20 million (“ELOC Commitment Note”). Although the ELOC provides for the issuance of the Commitment Shares, the Company did not issue any such shares during fiscal year 2025. The Company also entered into a Registration Rights Agreement requiring it to file a resale registration statement covering shares issuable under the ELOC.
As of June 30, 2026, 3,547,706 shares have been sold under the ELOC.
| 48 |
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, net sales, costs and expenses and related disclosures. We believe that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on our financial statements and, therefore, we consider these to be our critical accounting estimates. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. See “Note 1 – Nature of business and summary of significant accounting policies” to our interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a description of our significant accounting policies.
Share-Based Compensation
Share-based compensation expense is measured based on the estimated fair value of awards granted to employees, directors, officers and consultants on the grant date. Forfeitures are accounted for as they occur, therefore there are no forfeiture related estimates required.
The fair value of an option award is estimated on the date of grant using the Black–Scholes option valuation model, which requires the development of input assumptions, as described in “Note 15 – Share-based compensation”. Determining the appropriate fair value model and calculating the fair value of share-based payment awards requires the input of the subjective assumptions described in “Note 15 – Share-based compensation”. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. See “Note 15 – Share-based compensation” to our interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information.
Valuation of Derivative Liabilities and Equity-Linked Instruments
The Company’s accounting for convertible notes, embedded conversion features, and warrants requires the application of significant judgment, particularly in assessing the classification and measurement of these instruments under ASC 815, ASC 480, ASC 470, and other relevant guidance. In connection with the July 7, 2025 financing transaction and the October 28, 2025 issuance of the ELOC Commitment Note, the Company determined that the embedded conversion options within these instruments should be bifurcated and accounted for as derivative liabilities. These determinations required management to evaluate the economic characteristics of the conversion features, assess settlement alternatives, analyze the applicability of the scope exception under ASC 815-40, and determine whether the instruments qualify for equity classification.
The derivative liabilities associated with both the July 2025 senior secured convertible notes and the October 2025 ELOC Commitment Note are initially recorded at fair value and remeasured at each reporting date, with changes in fair value recognized in earnings. As a result, the Company’s reported results may experience significant non-cash volatility due to fluctuations in the market price of its common stock and changes in other valuation inputs.
The fair value of these derivative liabilities, as well as related equity-classified warrants, is estimated using option pricing models, including the Black-Scholes model or other appropriate valuation techniques. These models incorporate significant assumptions, including expected volatility of the Company’s common stock, risk-free interest rates, expected term, dividend yield, and the market price of the Company’s common shares. The ELOC Commitment Note includes a conversion feature with a variable discount tied to future trading prices, which increases valuation complexity and sensitivity to changes in stock price and volatility assumptions.
Because these inputs are inherently subjective and involve significant management judgment, actual results may differ materially from the estimates used. Changes in assumptions or market conditions, particularly volatility and stock price fluctuations, may have a material impact on the Company’s financial position and results of operations.
See “Note 13 – Preferred stock, warrants and other equity” and “Note 10 – Debt” to our interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.
Convertible Notes
The Company’s accounting for its senior secured convertible notes requires the use of significant judgment in applying the guidance in ASC 470-20, ASC 815, and ASC 835. Upon issuance of the Notes on July 7, 2025, management was required to evaluate the economic characteristics and risks of the embedded conversion feature to determine whether it should be separately accounted for. Based on this evaluation, the conversion option did not qualify for equity classification and was bifurcated as a derivative liability measured at fair value. This assessment required consideration of settlement alternatives, the terms of the host debt instrument, and the applicability of scope exceptions under U.S. GAAP. The initial measurement of the Notes also required allocation of proceeds among the debt host contract, the derivative liability, the original issue discount, and issuance costs, each of which impacts the effective interest rate recognized over the life of the Notes. The derivative liability is remeasured at fair value at each reporting date, with changes recorded in earnings, which may produce significant period-to-period volatility. The valuation of the derivative liability incorporates assumptions such as expected volatility, risk-free interest rates, expected term, and market price of the Company’s common shares, all of which involve considerable estimation uncertainty. Changes in these assumptions or market conditions could materially impact the recorded amounts for the Notes, the derivative liability, interest expense, and the Company’s results of operations. See “Note 10 – Debt” to our interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information.
| 49 |
| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this Item.
| ITEM 4. | CONTROLS AND PROCEDURES |
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of the three months ended June 30, 2026. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2026, our disclosure controls and procedures were effective. Notwithstanding this conclusion, we have determined that the condensed consolidated financial statements included in this Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.
Changes in Internal Control Over Financial Reporting
There has not been any change in our internal controls over financial reporting identified in connection with the evaluation that occurred during the quarter ended June 30, 2026 that has materially affected, or is reasonably likely to materially affect, those controls.
PART II
| ITEM 1. | LEGAL PROCEEDINGS |
From time to time, we are subject to litigation and other proceedings that arise in the ordinary course of our business. Subject to the inherent uncertainties of litigation and although no assurances are possible, we believe after discussing with legal counsel that there are no pending lawsuits or claims that, individually or in the aggregate, will have a material adverse effect on our business, financial condition or our yearly results of operations.
| ITEM 1A. | RISK FACTORS |
There have been no material changes from the risk factors described under the heading “Risk Factors” in our Annual Report filed on December 5, 2025. While we believe there have been no material changes from the risk factors previously disclosed, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report that could materially affect our business, financial condition or future results. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Quarterly Report, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
None.
| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
None.
| ITEM 4. | MINE SAFETY DISCLOSURES |
Not applicable.
| ITEM 5. | OTHER INFORMATION |
None.
| 50 |
| ITEM 6. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
The following exhibits are filed herewith.
EXHIBIT INDEX
| 51 |
|
† | Indicates a management contract or any compensatory plan, contract or arrangement. |
| * | Filed or furnished herewith. |
| # | Certain schedules and similar attachments to this agreement have been omitted in accordance with Item 601(b)(5) of Regulation S-K. The Company will furnish copies of any schedules or similar attachments to the SEC upon request. |
| *** | Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. |
| 52 |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SRx Health Solutions Inc. | ||
| Date: August 13, 2026 | By: | /S/ KENT CUNNINGHAM |
| Kent Cunningham | ||
Chief Executive Officer (Principal Executive Officer) | ||
| Date: August 13, 2026 | By: | /S/ CAROLINA MARTINEZ |
| Carolina Martinez | ||
Chief Financial Officer (Principal Financial and Accounting Officer) | ||
| 53 |